PHILADELPHIA The pandemic is helping U.S. abortion-rights advocates achieve a long-standing goal: Make it easier for women to use pills to end pregnancies up to 10 weeks.

Federal and state regulations have restricted access to medication abortion ever since the Food and Drug Administration approved it two decades ago. Nonetheless, use of the two-drug regimen has grown steadily, accounting for at least 40% of all abortions, even as the national abortion rate has fallen to historic lows, data show.

Before the coronavirus made seeking medical care in person risky for both patients and providers, efforts were well underway to expand access to abortion pills through telemedicine and mail-order pharmacies. Now, those efforts are accelerating and multiplying because suddenly a divisive political issue is also a matter of public health.

For patients seeking abortion, urgent modifications of current protocols are needed to ensure that patients can continue to obtain this time-sensitive treatment while limiting transmission of infection, 11 prominent reproductive health experts wrote last month in the journal Contraception.

The group, led by obstetrician-gynecologist Elizabeth Raymond, proposed reducing in-person clinic visits by eliminating ultrasounds and other tests that research shows are unnecessary for a safe, effective pill-induced abortion.

Planned Parenthood Southeastern Pennsylvania, which adopted the test-less approach in mid-March, quickly saw a shift. Although the total number of medication and surgical abortions remained about 800 a month, the proportion that used pills increased from 55% before the pandemic to 65% now.

We wouldnt be offering it if it werent safe, said Dayle Steinberg, president and CEO of the Southeastern Pennsylvania affiliate. The pandemic is showing us that we have to be nimble and adapt.

WHEN PRECAUTIONS BECOME DANGERS

Some background: Medication abortion starts with a pill called mifepristone, which blocks a hormone vital to pregnancy. That is followed 24 to 48 hours later by at least two misoprostol pills, which induce contractions. (Misoprostol is also used to treat stomach ulcers.)

In 2000, when the FDA made the controversial decision to approve mifepristone, it imposed stringent safety requirements. The drug can be dispensed only by specially certified health-care providers and only in clinics, hospitals, and medical offices not pharmacies like most prescription drugs.

Medical societies and public health experts have called on the FDA to remove the restrictions. Physician Jane E. Henney, FDA commissioner when mifepristone was approved, added her voice last year. Last month, so did Democratic Sens. Elizabeth Warren and Patty Murray, urging a reevaluation in light of the growing coronavirus disease pandemic.

The FDA has not budged, even though its own review says medication abortion has been increasingly used as its efficacy and safety have become well-established by both research and experience, and serious complications have proven to be extremely rare.

Advocates have not been deterred by the FDAs inflexibility.

Over the last year, Gynuity Health Projects a New York City-based nonprofit that Raymond joined in 2010 has expanded its FDA-approved study of medication abortion via telemedicine from five states to 13. It enables women to have video conferences with certified doctors, then get the pills mailed to them to take at home.

Still, Gynuitys TelAbortion has served fewer than 1,000 women over more than three years. Partly, thats because the FDA requires all study participants to have an initial in-person visit and an ultrasound to make sure they are no more than 10 weeks pregnant.

BENDING THE RULES

Studies have shown an ultrasound is unnecessary; only 1% of women do not accurately recall the date of their last menstrual period, and medication abortion still works for the vast majority of them. Other parts of the typical medication abortion protocol a pelvic exam, blood tests, and a return visit to confirm the termination are also unneeded, research shows.

Thats why Raymond and her 10 colleagues wrote the Contraception article, which laid out a protocol for evaluating, treating, and following up with patients in a way that would bend but not break the FDA rules.

Although FDA-imposed restrictions on mifepristone may require patients to present to the abortion facility to obtain the drug, this protocol would enable every other part of the medication abortion process to be implemented without any in-person encounter, they wrote.

Nothing like an epidemic to accelerate innovations, Raymond said in an interview.

Abortion foes denounce such innovations as endangering womens health. So far, 18 states have enacted various laws designed to ban the use of telemedicine in medication abortion. More recently, several states have tried to ban all abortions under pandemic emergency orders restricting elective medical procedures.

While the political divide is wider than ever, even abortion-rights activists dont agree on how much medical support women seeking medication abortion need or how best to provide it.

Numerous international websites ship abortion pills without prescription or any medical oversight to women who self-manage the termination in secret. Recognizing that the internet makes such uncounted abortions virtually unstoppable, public health researcher Elisa Wells cofounded Plan C, a website with a report card that rates such websites on product quality, price, and shipping time.

In early March, as the pandemic deepened, Plan C took another step toward helping women self-manage: It asked doctors across the country to register with one of the two FDA-approved manufacturers of mifepristone so they can obtain pills to mail to women in their homes.

FDA regulations say mifepristone must be dispensed in a facility, but Plan C maintains that dispensing is different than delivering.

Most doctors read the (FDA regulations) to say the pills cant be mailed, Wells said, adding that a handful of doctors have joined the new initiative. We disagree.

Aid Access, a mail-order abortion-pill service overseen by Dutch physician Rebecca Gomperts, has already been ordered to cease and desist by the FDA.

Gomperts set up Aid Access last year using the model of her first abortion-pill service, Women on Web, which serves women in countries were abortion is illegal. Basically, the pregnant woman consults online with the prescribing doctor, then gets a script to email to an Indian company that ships the pills. Instructions explain how to use the drugs, what to expect, and when to see a doctor if problems occur.

Although Gomperts didnt respond to a request for comment, she was recently quoted in the New York Times saying that the pandemic has fueled demand, with about 3,000 women requesting help from Aid Access since late March.

As for the FDA, Gomperts has a complaint against the agency pending in federal court. The FDA, she maintains, is trying to deny the constitutional right to abortion.

Dr. Gomperts has standing to assert the constitutional rights of her patients seeking medical abortions in the U.S., her legal brief says.

2020 The Philadelphia Inquirer

Visit The Philadelphia Inquirer at http://www.inquirer.com

Distributed by Tribune Content Agency, LLC.

PHOTO (for help with images, contact 312-222-4194):

Continued here:
Coronavirus pandemic is fueling efforts to increase access to abortion pills - yoursun.com

Recommendation and review posted by Bethany Smith

Disease education needed, especially in emergency or urgent care setting

Voices of Hypopara survey describes complex patient journey, and need for a strong patient and physician partnership

LEMOORE, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- In support of World Hypoparathyroidism Awareness Day, the HypoPARAthyroidism Association (HPA) today released findings of its recent survey highlighting the experiences of patients living with hypoparathyroidism (hypopara or HP) in the United States (U.S.). The Voices of Hypopara survey revealed that the majority of patients with this rare and complex endocrine disorder still struggle to receive adequate medical care, including in the emergency room (ER) or urgent care setting.

Hypoparathyroidism causes low levels of calcium in the blood due to insufficient amounts of parathyroid hormone. Hypoparathyroidism is mostly caused by thyroid (neck) surgery, but also results from idiopathic, genetic or autoimmune issues. It can lead to a wide range of physical and emotional symptoms, as well as severe long-term complications related to calcification in the kidney, brain, blood vessels, eye and other soft tissues.

In this survey of 146 people living with hypopara, an overwhelming 69% of participants reported experiencing a calcium crash’ a potentially life-threatening decrease in calcium levels at least once in the past year. Of these, 43% reported calcium crashes weekly or monthly, and 4% daily. A calcium crash can cause an inability to speak or breathe, involuntary or painful muscle spasms and even seizures.

Additionally, approximately 42% visited an ER and/or urgent care facility in the last year to address their symptoms; half of these visited two to four times, and another 18% visited the ER and/or urgent care even more often in the past year.

The survey also highlighted the complexity of the hypopara patient journey, including diagnosis. For half of the participants, it took more than five physician visits, and for a quarter of them, more than a year before receiving a diagnosis. In approximately 10% of participants, it took over a decade for their disorder to be diagnosed.

These striking results show that, while we’ve made great progress, we have more work to do to educate the medical community and public about hypopara, especially in the emergency setting,” said Deb Murphy, President and Vice Chair of the Board of Directors of the HypoPARAthyroidism Association. It was heartening to see that those participants who cited positive ER experiences said they played a key role in educating the staff about hypopara. Patients driving medical education and empowering themselves I can’t think of anything more exciting to see. By continuing on this path, I know we’ll be able to make a difference. It is an honor to be able to present the results of our survey and give voice to patients with hypopara on World Hypoparathyroidism Awareness Day.”

Results of the survey also provide insight to the experiences of those living with hypopara who seek emergency care:

In some cases, the calcium crash episodes are so serious they may require intravenous (IV) infusions of calcium in an ER or urgent care facility:

As an endocrinologist, managing hypoparathyroidism is one of the more complicated and challenging conditions. Greater awareness is needed across the healthcare community,” said Mishaela Rubin, M.D., a member of HypoPARAthyroidism Association’s Board of Medical Advisors. It is also critical that patients and physicians work together to anticipate and manage all the different aspects of this disease to minimize its day-to-day impact, and to reduce its burden to the healthcare system.”

Additional key findings include:

Of the 146 who participated in the survey, 89% were women and the average age was 51 years. The majority of participants (80%) were diagnosed after surgery; 11% were diagnosed due to idiopathic/unknown reasons; and 9% were diagnosed due to autoimmune or genetic causes.

About the Voices of Hypopara Survey The Voices of Hypopara research survey evaluated the experiences of 146 U.S. patients living with hypoparathyroidism (hypopara or HP), and was supported by Ascendis Pharma. The survey was fully anonymous and conducted online during April and May 2020.

About Hypoparathyroidism Hypoparathyroidism (hypopara or HP) is a rare endocrine disorder characterized by insufficient levels of parathyroid hormone (PTH), resulting in low calcium and elevated phosphate levels in the blood. The disorder affects approximately 200,000 patients in the United States (U.S.), Europe, Japan and South Korea, and at least 80,000 in the U.S. alone. The majority develop the condition following damage or accidental removal of the parathyroid glands during thyroid surgery. This condition can also be inherited or associated with other disorders.

Patients with hypopara often experience decreased quality of life. In the short term, symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment and headache. Over the long term, this complex disorder can cause major complications, such as calcium deposits occurring within the brain, eye, blood vessels and kidneys, which can lead to impaired renal function.

Until recently, hypopara remained among the few hormonal insufficiency states not treated by replacement of the missing hormone. Standard of care with active vitamin D analogs and calcium supplementation do not fully control this disorder, which contributes to a 4-fold to 8-fold greater risk of renal disease as compared to healthy individuals.

About the HypoPARAthyroidism Association The HypoPARAthyroidism Association is a nonprofit organization dedicated to improving the lives of people impacted by hypoparathyroidism and their caregivers through education, support, research and advocacy. Founded in 1994 by James Sanders, the Association has grown to include approximately 4,000 members in 70 countries and hosts an annual international conference to bring the medical and patient communities together for mutual exchange of how to treat and live with this rare disease. For more information, please visit http://www.hypopara.org.

Read the original:
New Survey on World Hypoparathyroidism Day Highlights Need for Awareness of this Rare Endocrine Disorder and Patient Challenges to Receive Adequate...

Recommendation and review posted by Bethany Smith

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ --Qualigen, Inc. Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPackSARS-CoV-2 IgG Immunoassay diagnostic test kits to the University of Louisville to conduct validation studies with hundreds of patient samples, as well as for use in research on COVID-19. SARS-CoV-2 is the virus that causes COVID-19.

Qualigen's SARS-CoV-2 IgG immunoassay, for use with its new FastPack PRO System point-of-care diagnostic instruments, is a chemiluminescent microparticle test intended for the qualitative detection (i.e., yes/no) of the presence of SARS-CoV-2 IgG antibodies in blood. The FastPack PRO System is an upgraded version of Qualigen's flagship FastPack IP rapid immunoassay diagnostic point-of-care system.

"This is an important step in the evolution of SARS-CoV-2 antibody testing, given the high number of inaccurate tests in the marketplace," said Michael Poirier, President, Chief Executive Officer and Chairman of Qualigen. "Reliable, accurate and rapid testing for the presence of antibodies is critical to understanding who may have been infected with SARS-CoV-2 and who could potentially have an immune response to re-infection."

Mr. Poirier continued, "Since its founding in my basement in Minnesota over 20 years ago, Qualigen has been continuously advancing this sophisticated rapid diagnostic technology, which is now used in physician offices, clinics and small hospital worldwide. I believe Qualigen is well suited to bring to market diagnostic systems that can improve our understanding and tracking of this disease as we strive to open up the U.S. economy."

Kenneth Palmer, PhD, Director of the University of Louisville Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases (CPM), and his research team will be conducting analytical validation studies on the FastPackSARS-CoV-2 IgG Immunoassay to provide Qualigen with validation data to submit to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization. The University of Louisville's CPM is one of only 12 infectious disease biocontainment facilities in the United States and is on the forefront of COVID-19 and infectious disease research.

"The ability to obtain rapid, accurate SARS-CoV-2 antibody data at the point of care for timely assessment of a patient's status is vital to the next phase of this pandemic. We are excited to be working with Qualigen on this important project," added Dr. Palmer.

About the FastPack SystemThe FastPack System is a rapid and highly accurate immunoassay testing system consisting of the FastPack Analyzer and the FastPack test pouch (a single-use, disposable, foil packet that includes the FastPack reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care. Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders and research applications. Over the past 20 years, FastPack has generated more than $100 million in commercial sales. Qualigen's worldwide distributor for FastPack is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company.

About Qualigen Therapeutics, Inc.Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack System, which has been used successfully in diagnostics for almost 20 years. The FastPack menu includes tests for cancer, men's health, hormone function and vitamin D status. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc. or to order FastPack diagnostic products, please visit https://www.qualigeninc.com/.

Forward-Looking StatementsThis news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that the validation studies for the proposed FastPackSARS-CoV-2 IgG Immunoassay diagnostic test kits will be timely conducted or will provide favorable validation data; that any request to the FDA for Emergency Use Authorization will be granted; that the Company will be able to manufacture the FastPack Pro System instruments and test kits successfully; that any commercialization of the FastPack Pro System instruments and test kits will be profitable; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that we will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products. Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at http://www.sec.gov. The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

View original content:http://www.prnewswire.com/news-releases/qualigen-therapeutics-releases-fastpack-sars-cov-2-antibody-diagnostic-test-to-university-of-louisville-to-conduct-validation-studies-301069009.html

SOURCE Qualigen, Inc.

Read the rest here:
Qualigen Therapeutics Releases FastPack SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies - BioSpace

Recommendation and review posted by Bethany Smith

With May being Mental Health Month, we sat down with Neill Epperson, MD, professor and chair of the CU Department of Psychiatry, for a wide-ranging conversation about expanding mental health resources and services to the CU Anschutz Medical Campus and broader community in the midst of the COVID-19 pandemic, her new Mind the Brain podcast, the state of mental health in Colorado, and why the brain is so intriguing.

CU Anschutz Today: How is the COVID-19 pandemic impacting our mental health?

Neill Epperson, MD: Depression, anxiety, insomnia, post-traumatic stress and increased use of alcohol and other substances are already on the rise and will likely be the second wave of this pandemic. Clearly, individuals who have experienced these problems in the past as well as those who are newly in the process of recovering from a mental health or substance use condition are at high risk for illness relapse.

However, other groups are also at risk. Those on the frontlines who are most proximal to the threat of illness, loss of their own life as well as that of their patients, are at high risk though they may experience a delay in onset of symptoms. It is not uncommon for those closest to the trauma, whether a natural disaster, terrorist attack or pandemic, to be so engaged in managing the crisis that they do not process the impact on their mental and physical health until the crisis subsides.

How does your new podcast, Mind the Brain: Mental Health in the Time of COVID-19, address the mental health challenges were facing amid the pandemic?

When social distancing first began, we realized that this was going to be a very difficult time for everyone. Human beings are very social creatures. Positive social contact helps us to manage our anxieties, distress, and uncertainties. During the first weeks of the pandemic the focus was on resilience and coping strategies. We and others provided many resources and tools via online and other virtual formats to help individuals of all ages and situations manage the crisis.

While resilience is clearly important to weathering this unprecedented global threat, I became increasingly concerned that our singular focus on resilience, support and coping could backfire resulting in increased stigma, diminishing an individuals willingness to seek formal mental health care. It is so easy to think that resilience means that we can take it, we can experience these tremendously adverse events and not experience insomnia, post-traumatic symptoms, depression or anxiety. In reality, resilience is far more complex. To admit that one is suffering takes tremendous strength. To overcome mental illness or a substance problem demonstrates true resilience.

Dr. Epperson recently launched the new podcast, Mind the Brain.

I was particularly concerned about my physician colleagues. We are trained to be team leaders, healers, to put our personal distress aside in order to provide the best care possible for our patients. While this is clearly part of our role, our mission, it can lead us to ignore our own needs for support and yes, psychological counseling and/or medications.

I created Mind the Brain: Mental Health in the Time of COVID-19 with the CU Anschutz Office of Communications as a forum for us to discuss mental illness, substance misuse and addictions in addition to resilience. All of the data we have at this time, indicates that mental illness is going to be the second wave of this pandemic. While we may have a vaccine in the coming month to years, the psychological sequelae of this pandemic will live on. My goal is to make sure that people can benefit from help, do not suffer in silence out of shame, guilt or lack of access to care.

How are you and your team working to expand mental health resources and services to the CU Anschutz campus and broader community in the wake of the COVID-19 pandemic?

In addition to the terrific resources on our website COVID-19 Support, we created a warmline for individuals who need rapid access to emotional support. We also created virtual support groups for students, residents, staff and clinical faculty and non-clinical faculty. We engaged with our colleagues at the University of Colorado Hospital and Childrens Hospital Colorado to offer virtual teams support groups. More than 400 people have used these groups to process clinical events, family stress, uncertainty, feelings of guilt and grief and anxieties about so many aspects of this pandemic. We have now been asked by public and mental health authorities to extend these resources across the State providing us with the opportunity to help an increasing number of Coloradans.

What fascinates you most about the brain?

Pretty much everything! Who we are, how we view ourselves, our personalities the processes that we refer to as the mind all of these are essentially rooted in the central nervous system- neural chemicals interacting with each other within and between functional neural networks. Some people don't like that definition of personality or the mind, because it sounds relatively reductionist: like all we are is just all a bunch of neurochemicals in our brain communicating with each other. I'm comfortable with that.

We dont judge how the heart works. We don't believe that the importance of the heart is diminished just because we understand that its function is to pump blood to the body. The importance of the brain is tantamount to how we function in the world today.

What is the relationship between mental health and physical health?

Mental health is about brain health. We can't separate brain health from the health of other organ systems.

There is a direct relationship between what happens in the central nervous system and other parts of the body. The brain controls many organ systems, and if your brain is not working well, then you can have illnesses in other parts of the body, and vice versa. If your heart is not working well blood flow to the brain can be compromised seriously impacting brain function, cognitive processes, and your mood. If you have an inflammatory problem, or cancer, or any number of other health conditions, the brain health can be adversely affected.

What's different about treating brain illnesses versus heart disease or a broken limb is that we are our brain to some degree. How we think about things, what we find funny, serious or worrisome, and our response to our environment, is very much driven by the central nervous system. We may worry that our personalities will change, that we may be cognitively impaired after our treatment. So treatments that impact our brain can be very scary, striking at the very core of who we are.

We also know that the environment that you grew up in whether you suffered poverty and maltreatment, or were lucky enough to have a very supportive, loving and well-resourced childhood can have an enduring effect on the brain. When treating central nervous system disorders like psychiatric or substance use conditions, it is important to consider these early life events. These events can impact how a person responds to both psychotherapies and pharmacotherapies.

Why can it be difficult for people to know if they need to seek mental health support?

What sometimes makes it difficult for people to know that they need to seek mental health care is that emotions are normal. Stress is normal. We all experience happiness, sadness, fear, anxiety, and stress. That difference between having emotions and having those emotions impact your functioning is a very difficult boundary to be able to distinguish.

It's tough for folks to know, "When do these emotions become problematic? How do I know when they're severe enough, or I feel sad enough long enough? Is my anxiety now reaching the point of panic? Does my anxiety get in the way of my going to work or going out and having fun with my friends?"

For people who think they may need mental health support, why is it often difficult for them to seek help?

Unfortunately, in 2020, stigma about mental health conditions is still rampant. Its one of the reasons people don't seek care. They think, "Im feeling a little sad, but I'll just get over it. The idea of talking about their issues can be very scary. And a lot of people don't really know what happens when you go and talk to a psychiatrist or a psychologist.

That difference between having emotions and having

those emotions impact your functioning is a very

difficult boundary to be able to distinguish.

What I tell people is that if you feel there's any question that you're not functioning as well as you would like to, then seeking help is the right way to go.

Why do you think stigma around mental health support is still so persistent?

One of the reasons I think stigma exists, but it's only one, is that people don't recognize that we actually have really good treatments for mental illness. People can get better. Many mental health conditions are actually curable.

Years ago, before we had really wonderful and effective treatments for cancer, cancer was highly stigmatized. I think that there is a direct benefit from knowing that what is bothering you the condition that you're experiencing actually has a name and is treatable. It's something that we have to make people aware of so that they understand it's true for psychiatric conditions as well as it is now true for cancer conditions.

How can we decrease the stigmatization of mental health conditions and the act of seeking treatment and support?

It will help decrease stigma the more we educate people about how common mental illness is. Fifty percent of people in the United States and worldwide are going to suffer with a mental health condition of some sort in their lifetime. In Colorado, one out of five individuals will have a mental health condition this year alone. How can you stigmatize something that is so common and affects so many people?

There is an immense need here in Colorado for mental health services. Unfortunately, we have about 25 counties where there is no practicing psychiatrist or psychologist, and that's just unacceptable. Even in counties where we do have psychiatrists, psychologists, and social workers, there are not enough to meet the mental health needs of that particular population or region. We have to do a better job of thinking strategically about how to get mental health services out to these other regions in the state.

What is the biggest difference in behavioral health research and treatment today, versus when you started working in this field?

When I first started my training in psychiatry in the 1990s, we had relatively few medications. Prozac was just released to the market. We had very few evidence-based psychotherapies to treat various psychiatric conditions, like post traumatic stress disorder, social anxiety, phobias, and OCD. We have these treatments now, and they are effective. We have much more information about the specific profile of the individual, the kinds of symptoms they experience, and how to modify our treatments to target those particular patient profiles.

Why did you choose to focus the majority of your clinical and research work on womens mental health?

I chose to study women, because at the time women were often left out of research not just in psychiatric research, but in medical research in general. Though women are increasingly included in research today, many investigators still do not examine outcomes by sex or gender. As a result, we know less about women than men in terms of how they respond to medications, and the kinds of treatment we should offer them.

We also know that hormones have a dramatic impact on brain health. Women undergo dramatic hormonal fluctuations every month when they have a menstrual cycle. I observed women in my practice developing depression, anxiety, psychosis, insomnia, and many different types of behavioral health conditions during these periods of hormonal fluctuation. I became fascinated by the profound effect hormones have on the brain.

From left, Drs. Nanette Santoro, Neill Epperson and Judy

Regensteiner map out the intersection of the primary issues

of focus for the Center for Womens Health Research.

Regensteiner is director and co-founder of the CWHR.

I am also fascinated by hormones because people don't mind talking about hormones. People might feel stigmatized if they talk about mental health, but talking about hormones is cool. You become the most popular person at the party when you tell people that you study hormone effects on the brain. People, particularly women, are curious about how hormones change the way they feel, think, and believe.

Where has your research and clinical work into the effect of hormones on the brain taken you?

Roughly one out of 10 women who have just given birth will experience depression or what we refer to as postpartum depression. They often feel that they're a bad mother, and they question why this is happening to them at a time when they're supposed to be so happy.

What most people do not realize is that pregnancy is like one big hormonal gymnastics. Women go from experiencing really high hormone levels during pregnancy to, within 24 hours after delivery, having those hormone levels plummet to their socks. That is a major adjustment for the brain. This concept is foreign to most people. They think, "It's a major adjustment for my body to deliver this baby, but they don't think about the fact that it's a major adjustment for their brain.

Can you talk about the important breakthrough your team made regarding pregnancy and the brain?

One of the major breakthroughs in the Department of Psychiatry this past year was the finding that choline, which is a nutrient in various foods, is critical to fetal brain development. We know that the in utero environment is one of the most important times in an individual's life. People think of birth as the start of life, but conception and what happens to the developing fetal brain during pregnancy is also critical for that individual's risk or resilience to mental health or mental illness later in life.

If a woman has low levels of choline during pregnancy, this can have an adverse effect on the fetus' neural development. Our researchers found that if you treat women with choline, you can decrease the negative effects of depression, anxiety, infection, and marijuana use during pregnancy on fetal brain development.

This is such an important finding that the American Medical Association has put forth guidelines recommending that women have a certain level of choline intake during pregnancy.

Given the fact that about 15 percent of women will experience depression during pregnancy, about a third of women are using cannabis at the time of conception at least here in Colorado and about 50 percent of women will have some kind of an infection during pregnancy, increasing choline levels during pregnancy could protect not only this generation from the adverse health effects of these maternal physical and psychological states, but generations to come.

How does being part of the CU Anschutz Medical Campus help you further your research into the brain and translate your findings into effective treatments?

One of the most exciting aspects of being a psychiatrist today and conducting research in neuroscience here on the CU Anschutz Medical Campus is that we have a number of state-of-the-art tools and techniques that allow us to access and understand how the brain is working far more than we ever have before.

For example, through deep-brain stimulation, we can put a probe in a very specific area of the brain to treat severe Obsessive Compulsive Disorder, or OCD. We can use brain imaging to visualize what happens when we give medications to patients, and to understand how early life adversity has an enduring impact on the way the brain functions when a person is performing a cognitive task. We can see the brain regions that are critical for those particular tasks.

We can measure neurochemistry in the brain, and how those neurochemicals interact with each other. This was unthinkable 20 years ago.

What have you learned from your research and clinical work about how early life experiences affect aging?

Early life experience can have an enduring impact on risk and resilience for depression, anxiety, cognitive outcomes, and even cognitive aging. On average, women today live a third of their lives in a post-menopausal state. We know that estrogen has a profound, positive effect on many aspects of brain function. To live a third of your life in a low- estrogen state was unheard of 100 years ago, when life expectancy for a woman meant she was likely to die around the time of menopause. For some women, living without estradiol is going to cause a problem. These are the people that I treat, and these are the people that I study. I want to understand Why them and not someone else?

One of the things we discovered is that early life adversity can have an impact on someone's risk for depression or cognitive changes when they go through menopause. Using functional brain imaging and novel neuroimaging techniques, weve seen that for people who have adverse childhood experiences, their brain actually functions differently when they try to do a complex cognitive task than somebody who didn't undergo those experiences. These cognitive changes can make it difficult for women to balance their home life, work life, and all the tasks they have to do.

As a psychiatrist, I can't go back and change what happened to one of my patients when they were a child, but if I give that post-menopausal woman estrogen, we may actually reverse the effects of those adverse childhood experiences.

What are your goals for the Department of Psychiatry and the communities you serve?

My goal for the Department of Psychiatry is that we are a top-five department in the nation. That means we're doing cutting-edge research that is impactful and changes peoples' lives. My goal for the state of Colorado is that we enable all Coloradans to live without mental illness and to enjoy the most fulfilling lives possible.

Our motto for the Department of Psychiatry is Brain health for all, for life. We believe every Coloradan should have access to state of the art evidence-based mental health care. We say "for life" because psychiatry and mental health are critical for a good life, and its reflective of our belief that one has to think about the whole lifespan of the patient when one considers the treatment of mental health conditions.

What keeps you up at night?

I try to get a good night sleep, because I believe sleep is important for mental health, but what keeps me up at night is knowing that there are people suffering needlessly from mental health conditions, either because they don't know that they're suffering from a clinical depression or anxiety disorder, they're afraid to seek treatment, or they feel stigmatized. When they do seek treatment, they find it challenging to find a provider they can afford. Those issues are very upsetting and very concerning. I know that we can do better. We must do better.

What do you find most gratifying about your work?

As a psychiatrist, youre often working with someone who comes to your office in tremendous psychological pain. That psychological pain actually can be experienced physically. When you can bring hope to that individual and then over the course of several weeks to months get them back to what they consider their normal state, it is exceptionally rewarding. You can see that pain falling away from them.

There is still much to learn, but the brain is not a black box anymore. It is complex, but let's face it: this is the organ that is at the seat of who we are. Don't we hope it's complex?

Read the original:
Q&A with Dr. Neill Epperson, Chair of the Department of Psychiatry - CU Anschutz Today

Recommendation and review posted by Bethany Smith

The proton pump inhibitor (PPI) omeprazole may be a useful addition to treatment for triple-negative breast cancer, as it boosted the expected rate of tumor disappearance among women with early-stage disease, according to the results of a phase 2 trial.

The trial results are presented online at the 2020 virtual annual meeting of the American Society of Clinical Oncology.

The rationale behind the approach includes the fact that PPIs inhibit fatty acid synthase (FASN), an enzyme overexpressed in 70% of newly diagnosed triple-negative breast cancers (TNBC) and associated with poor prognosis.

In the study, omeprazole, a generic drug for gastroesophageal reflux, was added to standard chemotherapy. Both were given to 42 women as neoadjuvant treatment in the weeks before breast surgery at five US centers in the single-arm study.

The pathologic complete response (pCR) rate was 71% in the study population, which is higher than the typical 40% seen in patients treated with standard AC-T (adriamycin and cyclophosphamide plus a taxane), said lead author Sagar Sardesai, MBBS, a medical oncologist at Ohio State Comprehensive Cancer Center in Columbus.

"It's exciting," said Sardesai in an interview with Medscape Medical News. "Overall, triple-negative patients who achieve a pCR have a very good outcome."

That complete disappearance of the tumor is a surrogate for overall survival in TNBC and patients who achieve it have a greatly reduced risk of recurrence or death, he explained.

Natalie Berger, MD, medical oncologist, Icahn School of Medicine at Mount Sinai, New York City, said the study's pCR rates were "much higher" than expected and "intriguing and hypothesis generating."

But Berger, who was not involved in the study, wanted to see more data.

"Having a non-chemotherapeutic agent to offer our patients with TNBC that improves pCR rates without added toxicity would be an exciting finding, but we need a larger randomized study," she said in an email.

The researchers, who include high-profile breast cancer specialist Kathy Miller, MD, of Indiana University, are seeking a National Cancer Institute or Department of Defense grant to mount a 100-plus patient randomized trial.

Sardesai explained that FASN, which is an enzyme, helps generate fatty acids that are a key to cancer cell survival. FASN is primarily found in hormone-dominated tissue such as those of the endometrium, prostate, and breast.

PPIs "selectively inhibit FASN activity and induce apoptosis in breast cancer cell lines with minimal effect on non-malignant cells," write the study authors in their meeting abstract.

The only other known agent known to inhibit FASN is the weight loss drug orlistat, which is poorly absorbed by the body and unlikely to impact cancer cells, Sardesai said.

FASN has been a potential drug target in TNBC for 10 to 15 years, but the first clinical evidence of efficacy in solid tumors was only seen in the last 5 years, he commented.

In 2015, Chinese investigators reported that the PPI esomeprazole in combination with chemotherapy produced a 5-month improvement in progression-free survival (vs chemo alone) among a subset of 15 TNBC patients in a randomized trial of 97 patients with a variety of breast cancer types.

The study was conducted in patients with early-stage, operable TNBC (with and without baseline FASN expression) and no prior PPI use within 12 months.

All patients started daily high-dose omeprazole 4 to 7 days prior to start of AC-T neoadjuvant chemotherapy (the addition of carboplatin was allowed per physician discretion) and continued until surgery.

The primary endpoint was pCR, defined as no residual invasive disease in breast or axilla, in patients with baseline FASN expression (FASN+).

The pCR rate was 71.4% in the 28 FASN+ patients and 71.8% in all 42 enrolled patients. The researchers had targeted a pCR rate of 60% in the FASN+ patients.

Also, among the subset of 15 patients who received carboplatin with AC-T, the pCR was 73%.

These two findings both have limitations, commented Berger.

She pointed out that it is "unexplained" as to why the pCR rates were similar among the FASN+ patients and the total population (including 14 FASN patients); the pCR rate would be expected to be lower in the total population, she suggested.

Further, it was also unexplained as to why there were similar pCR rates with or without carboplatin; other research has demonstrated improved pCR rates in patients receiving additional carboplatin (compared to AC-T alone) but at the cost of increased toxicity, she said.

Sardesai said that omeprazole was well tolerated with no known grade 3 or 4 toxicities and that the chemotherapy toxicity was similar to prior studies of AC-T. PPIs have side effects if taken for longer than a year, including a higher risk of infections, osteoporosis, and low magnesium, he also commented.

"Omeprazole can be safely administered in doses that inhibit FASN. The addition of high-dose omeprazole to neoadjuvant AC-T yields a promising pCR rate without adding toxicity," the authors conclude in their abstract.

Sardesai also highlighted the fact that using a PPI for breast cancer is an example of drug repurposing. The approach offers a way of rapid drug development because PPIs have complete safety and pharmacokinetics data available, he said. "If we can prove the efficacy, the treatment can move forward quickly and be available in clinical practice much sooner than with traditional drug development."

The study was funded by the Breast Cancer Research Foundation. Sardesai has financial ties to Novartis and Immunomedics. Other study authors have ties to industry. Berger has disclosed no relevant financial relationships.

American Society of Clinical Oncology (ASCO) 2020: Abstract 584

Follow Medscape's Nick Mulcahy on Twitter. For more from Medscape Oncology, follow us on Twitter.

Continue reading here:
PPI Added to Chemo Improves Breast Tumor Response Rate - Medscape

Recommendation and review posted by Bethany Smith

The Hematopoietic Stem Cell Transplantation (HSCT) Market report includes overview, which interprets value chain structure, industrial environment, regional analysis, applications, market size, and forecast. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. The report provides an overall analysis of the market based on types, applications, regions, and for the forecast period from 2020 to 2026. It also offers investment opportunities and probable threats in the market based on an intelligent analysis.

This report focuses on the Global Hematopoietic Stem Cell Transplantation (HSCT) Market trends, future forecasts, growth opportunities, key end-user industries, and market players. The objectives of the study are to present the key developments of the market across the globe.

Get a PDF Copy of the Sample Report for Free @ https://www.upmarketresearch.com/home/requested_sample/30593

Key List Market Participants in the Market:Regen Biopharma IncChina Cord Blood CorpCBR Systems IncEscape Therapeutics IncCryo-Save AGLonza Group LtdPluristem Therapeutics IncViaCord I

By Types:AllogeneicAutologous

By Applications:Peripheral Blood Stem Cells Transplant (PBSCT)Bone Marrow Transplant (BMT)Cord Blood Transplant (CBT)

Scope of the Hematopoietic Stem Cell Transplantation (HSCT) Market Report:

Fill the Pre-order Inquiry Form for the Report @https://www.upmarketresearch.com/home/enquiry_before_buying/30593

By Regions:North America (The USA, Canada, and Mexico)Europe (Germany, France, the UK, and Rest of Europe)Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Latin America (Brazil and Rest of Latin America.)Middle East &Africa (Saudi Arabia, the UAE, South Africa, and Rest of Middle East & Africa).

Report Answers Following Questions:

To Purchase This Report, Visit https://www.upmarketresearch.com/buy/hematopoietic-stem-cell-transplantation-market

Hematopoietic Stem Cell Transplantation (HSCT) Market Historic Data (2015-2019):

Hematopoietic Stem Cell Transplantation (HSCT) Market Forecast (2020-2026):

To Get this Report at an Incredible Discounts, Visit @ https://www.upmarketresearch.com/home/request_for_discount/30593

About UpMarketResearch:Up Market Research (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Organization UpMarketResearchAddress 500 East E Street, Ontario, CA 91764, United States.

Read more from the original source:
Hematopoietic Stem Cell Transplantation (HSCT) Market Demand Analysis and Projected huge Growth by 2025 - Bulletin Line

Recommendation and review posted by Bethany Smith

Human Mesenchymal Stem Cells (hMSC) Market Sales 2020-2026

Worldwide Human Mesenchymal Stem Cells (hMSC) Market Report 2020-2026 is a systematic and insightful compilation of valuable evaluations of Human Mesenchymal Stem Cells (hMSC) market and relevant aspects. The report offers an in depth exploration of the market and its scope, trends, structure, production, profitability and maturity.

The precise evaluation of market size, share, revenue, sales volume, demand, and rate of growth involved within the report drive investors, industry experts, researchers, also as novice and well-established market players to grasp the general Human Mesenchymal Stem Cells (hMSC) market structure.

Report: calibreresearch.com/report/est-sample The Human Mesenchymal Stem Cells (hMSC) market report also delivers an in-depth analysis of the emerging industry trends along side the restraints, key players, and opportunities within the Human Mesenchymal Stem Cells (hMSC) market to supply worthwhile insights also as a gift scenario for generating right decision.

Moreover, the new report on the Human Mesenchymal Stem Cells (hMSC) industry covers the prominent vendors within the universal market alongside SWOT analysis, fiscal overview and major developments. The world Human Mesenchymal Stem Cells (hMSC) Market report is considered as a detailed investigation of the respective market that will provide key solutions for establishment of profit-driven business strategies.

It is helpful for offering details about futuristic Human Mesenchymal Stem Cells (hMSC) industry trends and in-depth assessment of the international industry. It permits you to determine remarkable challenges and risk factors alongside major opportunities available in the world Human Mesenchymal Stem Cells (hMSC) market.

This report also exhibits the whole historical and current status of the Human Mesenchymal Stem Cells (hMSC) Market worldly. Apart from this, the report on the Human Mesenchymal Stem Cells (hMSC) industry also represents the graphical representation of the upcoming Human Mesenchymal Stem Cells (hMSC) Market infrastructure and the Compound Annual Growth Rate (CAGR) in detail.

Report: calibreresearch.com/report/for-buying

The report on the Human Mesenchymal Stem Cells (hMSC) market is an exclusive and deep study which delivers a comprehensive overview of the industry contains the recent trends and future proportions of the Human Mesenchymal Stem Cells (hMSC) market in terms of product and services. Meanwhile, this report offers a professional research study on the Human Mesenchymal Stem Cells (hMSC) market so as to guage the remarkable vendors by calibrating all the relevant products or services to know the positioning of the key players within the Human Mesenchymal Stem Cells (hMSC) market worldly.

Leading companies reviewed in the Human Mesenchymal Stem Cells (hMSC) report are: PromoCell ThermoFisher KURABO Lifeline Cell Technology Merck The Human Mesenchymal Stem Cells (hMSC) Market report is segmented into following categories: The product segment of the report offers product market information such as demand, supply and market value of the product. The application of product in terms of USD value is represented in numerical and graphical format for all the major regional markets.

The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Type by following categories; Umbilical Cord Matrix hMSC Bone Marrow hMSC Adipose Tissue hMSC Other The Human Mesenchymal Stem Cells (hMSC) market report is segmented into Application by following categories; Medical Application Research Other Applications

Report: calibreresearch.com/report/est-sample

The world Human Mesenchymal Stem Cells (hMSC) marketing research report offers an in depth summary of the foremost desirable factors and informative details about the universal industry. Moreover, the study provides an in-depth summary and forecast of the worldwide Human Mesenchymal Stem Cells (hMSC) market on the idea of several segments.

This report also delivers Human Mesenchymal Stem Cells (hMSC) market size and predicted estimations from the year 2020 to 2026 concerning various topological regions including Europe, North America, the center East and Africa, and South America. The research study on the Human Mesenchymal Stem Cells (hMSC) Market is a valuable source of guidance for world customers as it will rapidly fulfil their requirement and speed up their business growth.

It is an advantageous document for both existing industries manufactures including end-user industries, experts, managers, stakeholders and new entrants. We have designed this world Human Mesenchymal Stem Cells (hMSC) Market report in a deeply understandable format so that anyone can grasp each and every aspect related to the respective industry.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Go here to read the rest:
Human Mesenchymal Stem Cells (hMSC) Market investigated in the latest research - WhaTech Technology and Markets News

Recommendation and review posted by Bethany Smith

Celebrates milestone with registration of over 42,000 potential life savers in same time period in country

This World Blood Cancer Day, DKMS-BMST celebrates a milestone of registering over 42,000 potential lifesavers in a time period of one year in India. This group comprises of individuals who range from 18-50 years of age and have pledged to donate their blood stem cells to a blood cancer patient in need.

Focussed on helping patients with blood cancer and other blood disorders, DKMS-BMST has been able to save28unique lives in this period of one year including children diagnosed with blood cancer and other blood disorders like thalassemia.

Patients affected by blood cancer or thalassemia need a blood stem cell donation. Worldwide, only 30 per cent of them can find a match within their families and hence there is a dire need to find an unrelated donor. We started our operations in India last year with an intent to add potential blood stem cell donors of Indian ethnicity to the global database, so that patients (especially from this unique ethnicity) living in different parts of the world have a fair chance of finding a match and probably gain a second chance at life. We cannot thank enough, the people who are on-board and are helping us spread the word to add more and more people to this database,said Paul Patrick, CEO, DKMS BMST Foundation India.

Sharing his experience Mohd Saifulla, father to a 4-year-old thalassemia survivor said We went to multiple doctors trying to assess the problem our child had and thereafter to find a matching donor who could save her life. Receiving this transplant was the only chance of life for my daughter and we can never thank Debojyoti, a 28 year old software professional, enough, who donated his blood stem cells that matched our daughter. It is only because of organisations such as DKMS-BMST that people are coming forward to donate blood stem cells and save a life. My entire family is indebted to them for lifetime. Today my daughter is living a happy and healthy life and we are preparing to celebrate her fifth birthday this year that seemed like a dream to us up till a few years back.

Last year on World Blood Cancer Day, DKMS, one of the largest international blood stem cell donor centres in the world dedicated to the fight against blood cancer and blood disorders joined forces with Bangalore Medical Service Trust (BMST), a centre of excellence in blood banking, transfusion and immunohaematology adding India to the largest global repository of potential blood stem cell donors in the world. Every year, over 100,000 people in India are diagnosed with blood cancer or a blood disorder such asthalassemia or aplastic anaemia. Such life-threatening conditions can be managed by infusing a set of healthy blood stem cells from a suitable match. Since,ethnicity plays a crucial role in finding a matching donor, the ratio of potential blood stem cell donors from India needs to rise significantly, said Dr Latha Jagannathan, Director, DKMS BMST Foundation India.

Harsh, a blood stem cell donor registered with the foundation said,With very limited knowledge about blood stem cells I believed they were present only in the bone marrow and extracting them was a complex process. But to my surprise, the process is very similar to blood platelet donation. I strongly feel that anyone who is made aware that a simple process with zero complications can give you a chance to save a life will not hesitate from committing themselves towards the cause.

Capturing the challenges, the NGO faced in the country,Patrick said,We realised very early in India that a decision of this nature is not alone of the donor, but also involves his / her family. Hence, explaining the process, inculcating right awareness to break myths, updating people on the technological advances of blood stem cell donation and counselling them with medical experts has been our modus operandi in the country. Thus far, we have been able to conduct many physical drives to reach out to people urging them to register as potential donors. We plan to expand our reach to many more regions this year so that we are able to add potential donors from varied population groups in the country.

DKMS-BMST has organised over 1000donor registration drives in one year across various organisations such as corporates, educational institutes, hospitals and defence forces to spread awareness about blood stem cell donation and enroll more potential donors. Few names where physical drives have been conducted includes Mindtree, HSBC, HP enterprises, Christ University, RV College of Engineering, apart from public drives at Orion Mall Bengaluru, Lalbagh Botanical Garden etc.

In the current lockdown situation, the team is working tirelessly to ensure that patients whose donations were scheduled do not face any challenges and are organising awareness sessions through webinars and calling for registrations through the online portal:www.dkms-bmst.org/register.

Link:
DKMS-BMST Foundation India completes one year of operation in India - Express Healthcare

Recommendation and review posted by Bethany Smith

Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/11341

The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.

The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:

As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.

On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/11341

Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.

Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.

Read more:
Myelofibrosis Treatment Market to Create Lucrative Opportunities for Existing Companies as Well as New Players - Cole of Duty

Recommendation and review posted by Bethany Smith

On this page:BasicsComplementary TreatmentAlternative Treatment EffectivenessSide EffectsCancer Cure ScansDiet and Exercise

Youve seen the headlines about natural medicine trends, from yoga to supplements to diet and exercise fads. When it comes to cancer, you want to know what will help you safely regain your health during treatment and after. But there are loads of competing, sometimes-confusing info to sift through. What can you trust? Well, you can start with us here at HealthCentral: We went to the experts to learn all the science-based truth on complementary care for cancer.

First, lets clarify how cancer comes to be: Cancer occurs when abnormal cells anywhere in your body grow out of control, due to mutations in their DNA. Normal cells divide, age and die predictably, copying DNA as they go. Cancer cells, however, dont follow those rules. Rather than die off, they mutate, replicate, and form tumors.

Whats known as the primary site of your cancer is the spot where these cells start growing, and that organ or area determines the type of cancer you have. When cancerous cells journey through your blood or lymphatic system (the network of tissues and organs that flush out toxins, waste, and other undesirables), the areas they invade are metastatic sites.

Note that a cell can be abnormal without being cancerous (also known as malignant). It could be benign (not cancer), or precancerous or premalignant (likely to become cancer). Through screening and testing, docs can determine exactly what youre dealing with.

That depends on what kind of cancer you have, what stage its in, and other factors. Treatment can include:

Doctors often try more than one treatment, spaced out over weeks and months, as they gauge how your body responds. Your doc might even start you on multiple treatments at the same time.

Youve probably heard of complementary care. Or maybe you know it as alternative care. You know a bit of what these treatments might include (youre thinking meditation, herbs, and maybe yoga?). But did you know that while complementary and alternative care are often lumped together (as CAM, Complementary and Alternative Medicine), theyre not the same?

Complementary medicine is used in addition to conventional cancer care. It can include products, practices, and healthcare systems outside of mainstream medicine. These methods dont cure cancer, but work in conjunction with conventional cancer treatments to help in a variety of ways, including pain management and emotional support. Many complementary medicine practices can be considered evidence-based medicine (scientifically studied in randomized controlled trials, the highest level of evidence that guides cancer care).

When complementary medicine works harmoniously with conventional medicine, its an approach known as integrative medicine, or integrated care, where physicians treat you holisticallymeaning caring for you as a whole patient, taking into account all facets of your cancer experience. These can include:

When integrative medicine is administered to treat cancer, its known as integrative oncology, a patient-centered, evidence-informed field of cancer care. It may include:

Alternative medicine, in contrast, is used in place of conventional medicine. Rather than going hand-in-hand with, say surgery and chemo, alternative medicine is done instead of those evidence-based cancer treatments.

A quick note: before you try any new approach during (and after) your cancer treatment journey, make sure to discuss it with your doctor.

If youve used or are considering using complementary medicine as a cancer patient, youre not alonea national survey found that 65% of respondents whod been diagnosed with cancer had used some form of it.

Theres good reason to explore complementary care if you have cancer. It can be part of your supportive carehelping where you need it, like soothing and calming your mind and body as you go through this challenging time. Indeed, research suggests that complementary medicine can assist by:

There are easily hundreds of complementary treatments for cancer, so weve selected a small sample to discuss here. Possibilities include:

Acupuncture: Theres substantial evidence that this ancient Chinese practice of using sterile needles to stimulate different areas of the body can help manage cancer treatment-related nausea and vomiting. It may also help relieve cancer pain and other symptoms, but theres not enough evidence yet to support that.

Herbs: Ginger, for instance, has been shown to help control nausea from chemotherapy when used with conventional anti-nausea medications. Just keep in mind that any supplements you consume can change your body physiologicallynothing you ingest is without the potential for adverse effects. For instance, herbs can impact blood sugar levels and the bloods ability to clot.

Massage therapy: Sure, it feels sublime, and it turns out to have additional benefits too: research suggests that massage therapy can help relieve some cancer symptoms including:

Just be careful not to have deep tissue massage near surgery sites, tumors, or any medical devices. And always tell your therapist about your cancer diagnosis.

Meditation: Mindfulness-based meditation has been shown to improve quality of life during treatment. How? Studies of cancer patients have revealed the following happiness-boosting benefits:

Supplements: Herbal supplements for cancer could potentially help manage side effects like nausea and vomiting, pain, and fatigue, but more scientific evidence is required to make safe decisions about the use of these supplements.

Yoga: Preliminary data of this ancient mind/body practice from India suggests that those who do yoga could see improvements in these areas:

Another benefit: It might help lessen fatigue in breast cancer patients and survivors. More study into the myriad benefits of yoga is needed.

Other approaches: These include hypnosis, relaxation therapy, and biofeedback, all of which might help manage cancer symptoms and treatment side effects, based on study results.

One thing to note about all of these approaches: they might not be covered by your health insurance. According to the American Cancer Society, major insurers, including Blue Cross and Medicare, are starting to cover some complementary treatments. On the list above, acupuncture is most commonly covered. Contact your insurer to see what complementary treatments, if any, are paid for. They might be able to direct you to local providers who are covered under your plan.

When the treatments we discussed earlier (and the hundreds of others that are offered) are used in place of conventional medicine, its known as an alternative treatment. Nearly 40%, or 4 out of 10 Americans, believes that cancer can be cured by alternative treatments, a 2018 survey of cancer patients and people without cancer, found. However, while research shows that complementary medicine can play an important role in conventional cancer medicine, the same hasnt been readily found for alternative treatment.

Case in point: in 2009, the Society for Integrative Oncology (the leading international organization for healthcare professionals and researchers working in the field of complementary therapies in cancer care) published guidelines for healthcare professionals when using complementary medicine.

The org reminded healthcare professionals and patients that unproven cancer treatment methods shouldnt be used in place of conventional options because delaying cancer treatment thats evidence-based and shown to work reduces the chance of remission/cure for cancer patients.

Its important to talk with your healthcare professionals about the risks of using alternative therapies so you can make an informed decision about whats best for your health.

There are definite side effects with CAM. You might think that because something is natural, its safe. But this isnt always the case. Arsenic is natural, for instance, but you wouldnt want to start taking it in large doses.

Another example: Chemotherapy has a multitude of side effects because it destroys both cancerous cells and healthy cells. Its been cited by many as harmful because its made from chemicals. But did you know, some forms of chemo come from nature? Three drugs (Vincristine, Vinblastine, and Vinorelbine) are derived from plant alkaloids and are made from the periwinkle plant (Catharanthus Rosea). Chemo drugs called taxanes (Paclitaxel and Docetaxel) come from the bark of the Pacific Yew tree (Taxus).

Know too that just because something is sold, doesnt mean its been vetted or approved for usefor safety or qualityby the U.S. Food and Drug Administration (FDA). The FDA doesnt regulate vitamins and supplements, so the onus is on us to do our best to source safe, trustworthy products.

Its vital to tell your cancer healthcare team about every treatment and therapy youre using for your cancer, whether its receiving acupuncture for nausea, going to the chiropractor for pain, adding St. Johns Wort to your supplement regime to help manage depression, or getting a massage to feel better.

If youre reluctant to be open with your doc, youre not alone: 29% of cancer patients did not disclose their CAM practices to their providers, according to one study. Secret-keeping could be downright dangerous. Lets use these four seemingly innocuous examples to illustrate why:

Being open with your doc--both before you start a complementary treatment and while youre on it--is key to helping it complement, rather than detract, from the conventional care youre receiving.

When you have cancer, you of course want a cure (as quickly and painlessly as possible, please). But that desire can leave you vulnerable to fake claims, especially in the alternative medicine space. Both the FDA and the Federal Trade Commission (FTC) regularly warn the public about fraudulent cancer treatments.

It can be hard to spot the signs of snake oil. Without a medical degree, how can you be wise to empty promises? Youll often see the same language used in cancer CAM scams, according to the FDA. These phrases should raise a red flag that a treatment is just too good to be true:

Heres how you can protect yourself while receiving evidence-based integrated care:

You might be wondering now: with all this talk of complementary and alternative medicine, what about food? And diet? And exercise? What role does it play in all this? Is there a cancer diet that could be a complementary treatment?

Turns out, theres a strong body of evidence that a healthy diet and regular physical activity are associated with a reduced risk of cancer. The scientific literature links nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. Even after a cancer diagnosis, by making smart choices about what they put on their plate, patients can:

Food has power. To wield it, the American Institute for Cancer Research and American Cancer Society recommends you:

As for physical activity? While you should talk to your healthcare team about what kind and amount of exercise is safe during treatment, The American College of Sports Medicine (ACSM) has issued guidelines for physical activity for cancer survivors, suggesting 150-300 minutes per week of moderate to vigorous physical activity. Exercise is a real magic pill, helping to:

As you can imagine, all of these benefits that come along with being active are particularly important when youre trying to put cancer behind you. Resistance training, in particular, has been proven to improve:

Exercise, like so many CAM options, can help you both feel stronger and respond to treatment better. Just as with other types of complementary treatments, youll want to talk to your doc about how to integrate it, so you can reap the maximum benefits both from your lifestyle changes and your conventional cancer treatment.

Researchers have found that a healthy diet is associated with a reduced risk of cancer. Even if you have cancer, it can help lessen the impact of side effects and improve your quality of life. Studies link nutrition to cancer prevention based on specific physiologic pathways, including reducing inflammation, regulating hormones, and preventing oxidative stress. All to say that food matters.

Heres the thing: there are therapies that can help you go into remission (the period when your signs and symptoms of cancer are reduced). And some healthcare professionals consider cancer cured if it hasnt returned after five years (also called complete remission). Treatments that achieve a complete remission/cure can include therapies that come from a natural source, like some forms of chemo, which are derived from plant alkaloids. But anyone promising a natural cure for cancer that doesnt have evidence to back up that claim is likely pedaling bunk.

As weve discussed, herbs can be excellent complementary treatment in oncology for things like nausea, but any claim of curing cancer should be tempered by evidence-based medicine results (meaning, proof to back up those claims).

The American Academy of Dermatology warns that black salve isnt as safe as you might think, stating that it has never been proven to work. An article on the AADs website cites reports of bad outcomes for people who tried to treat their cancer (including melanoma) using black salve. The U.S. Food and Drug Administration (FDA) warns against products that are touted as cures for cancer without evidence: The FDA urges consumers to steer clear of these potentially unsafe and unproven products and to always discuss cancer treatment options with their licensed health care provider.

See original here:
Alternative and Complementary Treatments for Cancer - HealthCentral.com

Recommendation and review posted by Bethany Smith

COVID-19 impact will also be included and considered for forecast.

Global Cell Harvesting System Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Cell Harvesting System Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=153&RequestType=Sample

Cell Harvesting System Market: Increase in healthcare facilities and increase in bone marrow transplantation are key drivers for the Global Cell Harvesting System Market.

The global cell harvesting systems market size was valued USD 3533.27 Million in 2017 and is expected to grow at a CAGR of 14.01% over the forecast period.

Cell harvesting is a system which is used to cultivate, regenerate, transplant and repair the damages organs with the healthy one. Cell harvesting is one of the important parts of biopharmaceutical industry which directly relates with the quality of product. Stem cell harvesting also helps in the treatment of various diseases such as cancer, autoimmune disease, anemia and others. So, during the study of Global Cell Harvesting System market, we have considered Cell Harvesting System to analyze the market.

Global Cell Harvesting System Market report is segmented on the technique type, application type, end user type and by regional & country level. Based upon technique type, global Cell Harvesting System Market is classified as Altered Nuclear Transfer and Blastomere Extraction. Based upon Application type, global Cell Harvesting System Market is classified as Bone Marrow, Peripheral Blood, Umbilical Cord Blood, and Adipose Tissue. Based upon end users, global Cell Harvesting System Market is classified as Research Centers, Academics Institutes, Diagnostic Labs, and Hospitals.

The regions covered in this Cell Harvesting System Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Cell Harvesting System is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Cell Harvesting System Market Reports

Global Cell Harvesting System market report covers prominent players like Tomtec, Bertin Technologies, PerkinElmer Inc., TERUMO BCT, INC., SP Scienceware, hynoDent AG, Avita Medical, BRAND GMBH Teleflex Incorporated., Argos Technologies, Inc., Thomas Scientific, Arthrex, Inc. and others.

Global Cell Harvesting System Market Dynamics

The commercialization and growth of global Cell Harvesting System market over the past 25 years has been highly impactful. Bone marrow transplantation is one of the major factors driving the growth of cell harvesting system over the forecast period. Due to the increase in blood cancer it has raised the demand for bone marrow transplantation which in turn increased the demand for cell harvesting system. As per The Leukemia & Lymphoma Society report 2018, an estimated combined total of 174,250 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2018. There is also an increase in awareness about stem cells and its advantages which are helpful in the treatment of various disorders. Furthermore, various technological advancement have also increase the new and better technologies with better results are expected to promote the growth of cell harvesting system market over the forecast period. However, High cost, lack of reimbursement policies, immune rejection and others are the various factors which are expected to hamper the growth of cell harvesting system market over the forecast period.

Global Cell Harvesting System Market Regional Analysis

North America dominates the market with highest market share which is closely followed by the Europe over the forecast period. Due to the increased prevalence of leukemia, lymphoma and others coupled with increased healthcare facilities. As per The Leukemia & Lymphoma Society 2018 report, new cases of leukemia, lymphoma and myeloma are expected to account for 10 percent of the estimated 1,735,350 new cancer cases diagnosed in the US in 2018. Asia Pacific is expected to be the third largest and fastest growing region over the forecast period. Due to various technological advancements, increase in awareness among people and others are expected to support the growth of cell harvesting system market over the forecast period. Furthermore, Increase in healthcare facilities in the developing economies such as India, China and others are expected to fuel the growth of cell harvesting system market. Latin America, Middle East and Africa and expected to develop at a considerable rate over the forecast period.

Key Benefits for Global Cell Harvesting System Market Reports

Global Cell Harvesting System market report covers in depth historical and forecast analysis.Global Cell Harvesting System Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Cell Harvesting System Market report helps to identify opportunities in market place.Global Cell Harvesting System Market report covers extensive analysis of emerging trends and competitive landscape.

By Techniques Type:

Altered Nuclear TransferBlastomere Extraction

By Application:

Bone MarrowPeripheral BloodUmbilical Cord BloodAdipose Tissue

By End User:

Research CentersAcademics InstitutesDiagnostic LabsHospitals

By Region

North AmericaU.S.CanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilMexicoThe Middle East and AfricaGCCAfricaRest of Middle East and Africa

Cell Harvesting System Market Key PlayersTomtecBertin TechnologiesPerkinElmer Inc.TERUMO BCT, INC.SP SciencewarehynoDent AGAvita MedicalBRAND GMBHTeleflex Incorporated.Argos Technologies, Inc.Thomas ScientificArthrex, Inc.

Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=153&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Cell Harvesting System Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Cell Harvesting System Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Cell Harvesting System Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Cell Harvesting System Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Cell Harvesting System Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Cell Harvesting System Market.

Market Forecast: Here, the report offers a complete forecast of the Global Cell Harvesting System Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Top Trending Reports:

Top Trending Reports:

Here is the original post:
Covid 19 Outbreak Cell Harvesting System Market 2020 Product Type, Applications/end user, Key Players and Geographical Regions 2026 - Jewish Life...

Recommendation and review posted by Bethany Smith

"There are so many unanswered questions, so many puzzles we are yet to solve," she said.

Dr Bart should have been on a plane on Monday, bound for Harvard University and the Brigham and Women's Hospital in Massachusetts for her 10-month Fulbright exchange placement, collaborating with fellow bright minds to unravel the complexities of cardiac genetics.

The Fulbright Program is a highly coveted US foreign exchange scholarship program, aimed at increasing bi-national research collaboration, cultural understanding and the exchange of ideas.

The COVID-19 pandemic has waylaid Dr Bart's travel plans and diverted her attention to the effects of the virus on cardiac patients. But she is continuing her research into the genetic roots of cardiac disease, in particular cardiac amyloidosis, where abnormal protein deposits amyloid fibrils build up in heart tissue, causing heart failure.

Amyloid heart disease used to be a death sentence, Dr Bart said.

"By the time we see patients and diagnose them, it's often too late. We had no treatment we could offer these patients until very recently," she said. "Now that we have those treatments we have a clinical imperative to diagnose early [using genetic testing].

"We are on this cusp of a genetics and genomic revolution where patients can be offered treatment based on their individual genetic make-up," Dr Bart said. "It's hugely exciting".

Being on the cusp of scientific breakthroughs seems like a fitting spot for the expert mountaineer. Dr Bart and her mother, Cheryl Bart, were first mother-daughter team to summit Everest and complete the "Seven Summits" challenge climbing the highest mountains on each continent.

Loading

"I appreciate what it feel like to push your body to the extreme," she said.

"The thing about being in high altitudes, up about 8000 metres, you have to focus on the next step and breath. There's a mindfulness to that focus, and not worrying about the bigger problem. You have a plan in place and you just keep taking that next step."

It's an ethos she brings to her research in the male-dominated field. Women account for just 15 per cent of cardiologists in Australia.

"There is still a huge gender gap, and this is likely affecting outcomes in research," she said. "The fascinating thing about women's hearts is that they behave different to men's. The signs and symptoms are different. Women don't have that thumping elephant-on-the-chest pain. They have more subtle symptoms.

"It's imperative that we have more female specialists and we utilise our different ways of thinking. We need more people to think laterally and collaborate."

Associate Professor Anthony Schembri, chief executive officer at St Vincent's Hospital, described Dr Bart as "a compassionate specialist who cares deeply for each of her patients, at the same time as undertaking research from the bench to the bedside with the aim of achieving long-term improved outcomes in her field of cardiac genetics".

Loading

Victor Chang Cardiac Research Institute executive director Professor Jason Kovacic said Dr Bart was "one of the many inspiring women in science, a trailblazer, pushing the boundaries and paving the way for hopefully more women considering a career as a researcher".

"It is a great honour to be awarded a Fulbright scholarship, and it is a reflection of Dr Bart's dedication to be at the forefront of medical research and ensure that studies are not undertaken in isolation but rather in collaboration with global partners to truly make a difference for patients suffering from heart disease," he said.

Kate Aubusson is Health Editor of The Sydney Morning Herald.

View post:
Sydney cardiologist honoured with Fulbright scholarship - Sydney Morning Herald

Recommendation and review posted by Bethany Smith

CORAL SPRINGS, FL Swimming coach. Fire equipment. Medical evaluations.

These were among the projects and expenses approved Wednesday by Coral Springs City Commission at a cost of at least $679,800.

Heres what commissioners approved during their June 3 public meeting:

Our newsletter delivers the local news that you can trust.

- Swim coach services from July 1, 2020 to June 30, 2022. Swim Phish, Inc. of Coral Springs will get annual stipend of $25,000.

- Fire equipment parts, supplies, and service from July 1, 2020 to June 30, 2021. Ten-8 Fire Equipment, Inc. of Bradenton, Fla, will get estimated annual payment of $75,000.

- Tandem axle truck. SBL Freightliner LLC/Lou Bachrodt Freightliner of Pompano Beach will be paid $127,170.

- Maintenance and inspection of building automation systems citywide from June 4, 2020 to June 3, 2021. Design Controls, Inc/DCI Systems Group, Inc. of Oakland Park will get annual payment of up to $100,000.

- Medical evaluations/physicals. Life Extension Clinics, Inc. of Tampa will get annual payment of $140,000.

- Security guard services from June 16 to March 8, 2025. Universal Protection Service, LLC/Allied Universal Security Services, LLC of Santa Ana, Ca. will get annual payment of $212,800.

Follow us on Facebook and Twitter and sign up for FREE TAPinto Coral Springs E-News alerts to be the first to read about all things Coral Springs.

Download the FREE TAPinto App.Click here for Android-Click here for iOSfor breaking news, traffic/weather alerts, and special offers.

Know a story we should share with our readers? Email editor Leon Fooksman (lfooksman@tapinto.net) and tell him about it.

Read more from the original source:
Coral Springs Approves Spending of At Least $679800 on Projects and Expenses - TAPinto.net

Recommendation and review posted by Bethany Smith

This detailed market study covers eye health supplements market growth potentials which can assist the stake holders to understand key trends and prospects in eye health supplements market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the markets growth potential, which can help investors identify scope and opportunities. The analysis also provides details of each segment in the global eye health supplements market

Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-67629?utm_source=AZ&utm_medium=SG

According to the report, the eye health supplements market report points out national and global business prospects and competitive conditions for eye health supplements. Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for eye health supplements. The eye health supplements market has been segmented by ingredient type (lutein and zeaxanthin, antioxidants, omega-3 fatty acids, coenzyme q10, flavonoids, astaxanthin, alpha-lipoic acid, other ingredients), by indication type (age-related macular degeneration (amd), cataract, dry eye syndrome, other indications), by form (tablet, capsule, others). Historical background for the demand of eye health supplements has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand eye health supplements have also been established with potential gravity.

Regional segmentation and analysis to understand growth patterns:

The market has been segmented in major regions to understand the global development and demand patterns of this market.

North America, Europe, and Asia Pacific by region are estimated to dominate the eye health supplements market during the forecast period. These regions have been market leaders for the overall healthcare sector in terms of technological developments and advanced medical treatments. Moreover, the government policies have been favourable for the growth of the healthcare infrastructure in these regions. North America and Europe have an established healthcare infrastructure for product innovations and early adaptations. This is expected to drive the demand for eye health supplements market during the forecast period.

Get ToC for the overview of the premium report @https://www.quincemarketinsights.com/request-toc-67629?utm_source=AZ&utm_medium=SG

The US, Germany, France, UK, Canada, and Spain have been some the major markets in the region. Asia Pacific is estimated to register one of highest CAGR for eye health supplements market during the forecast period. This region has witnessed strategic investments by global companies to cater the growing demand in the recent years. China, Japan, India, South Korea, and Australia are amongst some of the key countries for eye health supplements market in the region. Other regions including Middle East, Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets for eye health supplements market during the forecast period.

This report provides:

1) An overview of the global market for eye health supplements market and related technologies.2) Analysis of global market trends, yearly estimates and annual growth rate projections for compounds (CAGRs).

3) Identification of new market opportunities and targeted consumer marketing strategies for global eye health supplements market .4) Analysis of R&D and demand for new technologies and new applications5) Extensive company profiles of key players in industry.

Make an Inquiry for purchasing this Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-67629?utm_source=AZ&utm_medium=SG

The researchers have studied the market in depth and have developed important segments such as product type, application and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

With an emphasis on strategies there have been several primary developments done by major companies such as Vitabiotics Ltd., Valeant Pharmaceuticals International Inc., Life Extension, Pfizer Inc., OmniActive Health Technologies, Algatechnologies, Alliance Pharma, The Natures Bounty Co., Novartis AG, and Amway Corp.

Market Segmentation:

By Ingredient Type:o Lutein and Zeaxanthino Antioxidantso Omega-3 Fatty Acidso Coenzyme Q10o Flavonoidso Astaxanthino Alpha-Lipoic Acido Other Ingredients

By Indication Type:o Age-related Macular Degeneration (AMD)o Cataracto Dry Eye Syndromeo Other Indications

By Form:o Tableto Capsuleo Others

By Region:

North America Eye Health Supplements Marketo North America, by CountryUSCanadaMexicoo North America, by Ingredient Typeo North America, by Indication Typeo North America, by Form

Europe Eye Health Supplements Marketo Europe, by CountryGermanyRussiaUKFranceItalySpainThe NetherlandsRest of Europeo Europe, by Ingredient Typeo Europe, by Indication Typeo Europe, by Form

Asia Pacific Eye Health Supplements Marketo Asia Pacific, by CountryChinaIndiaJapanSouth KoreaAustraliaIndonesiaRest of Asia Pacifico Asia Pacific, by Ingredient Typeo Asia Pacific, by Indication Typeo Asia Pacific, by Form

Middle East & Africa Eye Health Supplements Marketo Middle East & Africa, by CountryUAESaudi ArabiaQatarSouth AfricaRest of Middle East & Africao Middle East & Africa, by Ingredient Typeo Middle East & Africa, by Indication Typeo Middle East & Africa, by Form

South America Eye Health Supplements Marketo South America, by CountryBrazilArgentinaColombiaRest of South Americao South America, by Ingredient Typeo South America, by Indication Typeo South America, by Form

Reasons to Buy This Report:

o Provides niche insights for decision about every possible segment helping in strategic decision making process.o Market size estimation of the eye health supplements market on a regional and global basis.

o A unique research design for market size estimation and forecast.o Identification of major companies operating in the market with related developmentso Exhaustive scope to cover all the possible segments helping every stakeholder in the eye health supplements

Customization:

This study is customized to meet your specific requirements:

o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis

Contact:Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: US +1 208 405 2835 UK +44 121 364 6144 APAC +91 706 672 4848Email: sales@quincemarketinsights.comWeb:www.quincemarketinsights.com

ABOUT US:QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

See original here:
Eye Health Supplements Market : Prospective Growth Trends & Incremental Opportunity Assessment till... - Azizsalon News

Recommendation and review posted by Bethany Smith

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Reishi Mushroom Supplements market. It informs readers about key trends and opportunities in the global Reishi Mushroom Supplements market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Reishi Mushroom Supplements market.

Key companies operating in the global Reishi Mushroom Supplements market include , Natures Way Reishi, Solaray Reishi Mushroom, Life Extension Reishi Extract, Host Defense Reishi, Terrasoul Superfoods, Swanson Reishi Mushroom, Aloha Medicinals, Mushroom Science, Planetary Herbals Reishi Mushroom Supplements

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1733074/global-reishi-mushroom-supplements-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Reishi Mushroom Supplements market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Reishi Mushroom Supplements Market Segment By Type:

, Organic Reishi Mushroom Supplements, Inorganic Reishi Mushroom Supplements Reishi Mushroom Supplements

Global Reishi Mushroom Supplements Market Segment By Application:

, Online Sales, Offline Sales

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Reishi Mushroom Supplements market.

Key companies operating in the global Reishi Mushroom Supplements market include , Natures Way Reishi, Solaray Reishi Mushroom, Life Extension Reishi Extract, Host Defense Reishi, Terrasoul Superfoods, Swanson Reishi Mushroom, Aloha Medicinals, Mushroom Science, Planetary Herbals Reishi Mushroom Supplements

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1733074/global-reishi-mushroom-supplements-market

TOC

1 Study Coverage1.1 Reishi Mushroom Supplements Product Introduction1.2 Market Segments1.3 Key Reishi Mushroom Supplements Manufacturers Covered: Ranking by Revenue1.4 Market by Type 1.4.1 Global Reishi Mushroom Supplements Market Size Growth Rate by Type 1.4.2 Organic Reishi Mushroom Supplements 1.4.3 Inorganic Reishi Mushroom Supplements1.5 Market by Application 1.5.1 Global Reishi Mushroom Supplements Market Size Growth Rate by Application 1.5.2 Online Sales 1.5.3 Offline Sales1.6 Coronavirus Disease 2019 (Covid-19): Reishi Mushroom Supplements Industry Impact 1.6.1 How the Covid-19 is Affecting the Reishi Mushroom Supplements Industry 1.6.1.1 Reishi Mushroom Supplements Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Reishi Mushroom Supplements Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Reishi Mushroom Supplements Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Reishi Mushroom Supplements Market Size Estimates and Forecasts 2.1.1 Global Reishi Mushroom Supplements Revenue 2015-2026 2.1.2 Global Reishi Mushroom Supplements Sales 2015-20262.2 Reishi Mushroom Supplements Market Size by Region: 2020 Versus 2026 2.2.1 Global Reishi Mushroom Supplements Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Reishi Mushroom Supplements Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Reishi Mushroom Supplements Competitor Landscape by Players3.1 Reishi Mushroom Supplements Sales by Manufacturers 3.1.1 Reishi Mushroom Supplements Sales by Manufacturers (2015-2020) 3.1.2 Reishi Mushroom Supplements Sales Market Share by Manufacturers (2015-2020)3.2 Reishi Mushroom Supplements Revenue by Manufacturers 3.2.1 Reishi Mushroom Supplements Revenue by Manufacturers (2015-2020) 3.2.2 Reishi Mushroom Supplements Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Reishi Mushroom Supplements Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Reishi Mushroom Supplements Revenue in 2019 3.2.5 Global Reishi Mushroom Supplements Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Reishi Mushroom Supplements Price by Manufacturers3.4 Reishi Mushroom Supplements Manufacturing Base Distribution, Product Types 3.4.1 Reishi Mushroom Supplements Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Reishi Mushroom Supplements Product Type 3.4.3 Date of International Manufacturers Enter into Reishi Mushroom Supplements Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Reishi Mushroom Supplements Market Size by Type (2015-2020) 4.1.1 Global Reishi Mushroom Supplements Sales by Type (2015-2020) 4.1.2 Global Reishi Mushroom Supplements Revenue by Type (2015-2020) 4.1.3 Reishi Mushroom Supplements Average Selling Price (ASP) by Type (2015-2026)4.2 Global Reishi Mushroom Supplements Market Size Forecast by Type (2021-2026) 4.2.1 Global Reishi Mushroom Supplements Sales Forecast by Type (2021-2026) 4.2.2 Global Reishi Mushroom Supplements Revenue Forecast by Type (2021-2026) 4.2.3 Reishi Mushroom Supplements Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Reishi Mushroom Supplements Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Reishi Mushroom Supplements Market Size by Application (2015-2020) 5.1.1 Global Reishi Mushroom Supplements Sales by Application (2015-2020) 5.1.2 Global Reishi Mushroom Supplements Revenue by Application (2015-2020) 5.1.3 Reishi Mushroom Supplements Price by Application (2015-2020)5.2 Reishi Mushroom Supplements Market Size Forecast by Application (2021-2026) 5.2.1 Global Reishi Mushroom Supplements Sales Forecast by Application (2021-2026) 5.2.2 Global Reishi Mushroom Supplements Revenue Forecast by Application (2021-2026) 5.2.3 Global Reishi Mushroom Supplements Price Forecast by Application (2021-2026) 6 North America6.1 North America Reishi Mushroom Supplements by Country 6.1.1 North America Reishi Mushroom Supplements Sales by Country 6.1.2 North America Reishi Mushroom Supplements Revenue by Country 6.1.3 U.S. 6.1.4 Canada6.2 North America Reishi Mushroom Supplements Market Facts & Figures by Type6.3 North America Reishi Mushroom Supplements Market Facts & Figures by Application 7 Europe7.1 Europe Reishi Mushroom Supplements by Country 7.1.1 Europe Reishi Mushroom Supplements Sales by Country 7.1.2 Europe Reishi Mushroom Supplements Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia7.2 Europe Reishi Mushroom Supplements Market Facts & Figures by Type7.3 Europe Reishi Mushroom Supplements Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Reishi Mushroom Supplements by Region 8.1.1 Asia Pacific Reishi Mushroom Supplements Sales by Region 8.1.2 Asia Pacific Reishi Mushroom Supplements Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam8.2 Asia Pacific Reishi Mushroom Supplements Market Facts & Figures by Type8.3 Asia Pacific Reishi Mushroom Supplements Market Facts & Figures by Application 9 Latin America9.1 Latin America Reishi Mushroom Supplements by Country 9.1.1 Latin America Reishi Mushroom Supplements Sales by Country 9.1.2 Latin America Reishi Mushroom Supplements Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina9.2 Central & South America Reishi Mushroom Supplements Market Facts & Figures by Type9.3 Central & South America Reishi Mushroom Supplements Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Reishi Mushroom Supplements by Country 10.1.1 Middle East and Africa Reishi Mushroom Supplements Sales by Country 10.1.2 Middle East and Africa Reishi Mushroom Supplements Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 U.A.E10.2 Middle East and Africa Reishi Mushroom Supplements Market Facts & Figures by Type10.3 Middle East and Africa Reishi Mushroom Supplements Market Facts & Figures by Application 11 Company Profiles11.1 Natures Way Reishi 11.1.1 Natures Way Reishi Corporation Information 11.1.2 Natures Way Reishi Description, Business Overview and Total Revenue 11.1.3 Natures Way Reishi Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Natures Way Reishi Reishi Mushroom Supplements Products Offered 11.1.5 Natures Way Reishi Recent Development11.2 Solaray Reishi Mushroom 11.2.1 Solaray Reishi Mushroom Corporation Information 11.2.2 Solaray Reishi Mushroom Description, Business Overview and Total Revenue 11.2.3 Solaray Reishi Mushroom Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Solaray Reishi Mushroom Reishi Mushroom Supplements Products Offered 11.2.5 Solaray Reishi Mushroom Recent Development11.3 Life Extension Reishi Extract 11.3.1 Life Extension Reishi Extract Corporation Information 11.3.2 Life Extension Reishi Extract Description, Business Overview and Total Revenue 11.3.3 Life Extension Reishi Extract Sales, Revenue and Gross Margin (2015-2020) 11.3.4 Life Extension Reishi Extract Reishi Mushroom Supplements Products Offered 11.3.5 Life Extension Reishi Extract Recent Development11.4 Host Defense Reishi 11.4.1 Host Defense Reishi Corporation Information 11.4.2 Host Defense Reishi Description, Business Overview and Total Revenue 11.4.3 Host Defense Reishi Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Host Defense Reishi Reishi Mushroom Supplements Products Offered 11.4.5 Host Defense Reishi Recent Development11.5 Terrasoul Superfoods 11.5.1 Terrasoul Superfoods Corporation Information 11.5.2 Terrasoul Superfoods Description, Business Overview and Total Revenue 11.5.3 Terrasoul Superfoods Sales, Revenue and Gross Margin (2015-2020) 11.5.4 Terrasoul Superfoods Reishi Mushroom Supplements Products Offered 11.5.5 Terrasoul Superfoods Recent Development11.6 Swanson Reishi Mushroom 11.6.1 Swanson Reishi Mushroom Corporation Information 11.6.2 Swanson Reishi Mushroom Description, Business Overview and Total Revenue 11.6.3 Swanson Reishi Mushroom Sales, Revenue and Gross Margin (2015-2020) 11.6.4 Swanson Reishi Mushroom Reishi Mushroom Supplements Products Offered 11.6.5 Swanson Reishi Mushroom Recent Development11.7 Aloha Medicinals 11.7.1 Aloha Medicinals Corporation Information 11.7.2 Aloha Medicinals Description, Business Overview and Total Revenue 11.7.3 Aloha Medicinals Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Aloha Medicinals Reishi Mushroom Supplements Products Offered 11.7.5 Aloha Medicinals Recent Development11.8 Mushroom Science 11.8.1 Mushroom Science Corporation Information 11.8.2 Mushroom Science Description, Business Overview and Total Revenue 11.8.3 Mushroom Science Sales, Revenue and Gross Margin (2015-2020) 11.8.4 Mushroom Science Reishi Mushroom Supplements Products Offered 11.8.5 Mushroom Science Recent Development11.9 Planetary Herbals 11.9.1 Planetary Herbals Corporation Information 11.9.2 Planetary Herbals Description, Business Overview and Total Revenue 11.9.3 Planetary Herbals Sales, Revenue and Gross Margin (2015-2020) 11.9.4 Planetary Herbals Reishi Mushroom Supplements Products Offered 11.9.5 Planetary Herbals Recent Development11.1 Natures Way Reishi 11.1.1 Natures Way Reishi Corporation Information 11.1.2 Natures Way Reishi Description, Business Overview and Total Revenue 11.1.3 Natures Way Reishi Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Natures Way Reishi Reishi Mushroom Supplements Products Offered 11.1.5 Natures Way Reishi Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Reishi Mushroom Supplements Market Estimates and Projections by Region 12.1.1 Global Reishi Mushroom Supplements Sales Forecast by Regions 2021-2026 12.1.2 Global Reishi Mushroom Supplements Revenue Forecast by Regions 2021-202612.2 North America Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.2.1 North America: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.2.2 North America: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.2.3 North America: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026)12.3 Europe Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.3.1 Europe: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.3.2 Europe: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.3.3 Europe: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Reishi Mushroom Supplements Market Size Forecast by Region (2021-2026)12.5 Latin America Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.5.1 Latin America: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.5.2 Latin America: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.5.3 Latin America: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Reishi Mushroom Supplements Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Reishi Mushroom Supplements Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Reishi Mushroom Supplements Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Reishi Mushroom Supplements Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Reishi Mushroom Supplements Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Reishi Mushroom Supplements Customers14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source16.2 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Here is the original post:
Reishi Mushroom Supplements Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Weekly...

Recommendation and review posted by Bethany Smith

VANCOUVERThe crucial piece of safety equipment that offered the last chance to save the life of Capt. Jenn Casey when she ejected from a Snowbird CT-114 Tutor Jet earlier this month had been targeted for replacement by a much more sophisticated system as far back as 2015, military records show.

Twelve days after the tragedy, the military wont say whether the Canadian Forces fleets ejection seats have yet been replaced, or whether the ejection seats used by Casey and pilot Capt. Richard MacDougall that day were still an outdated technology that the military knew was less effective at saving lives in the flying conditions used by the Snowbirds than more modern systems.

Although the cause of the crash that took place in Kamloops, B.C., moments after the Snowbirds CT-114 Tutor Jet took off is not yet publicly known, one thing is certain: MacDougall and Casey both ejected from the plane, their lives depending on the absolute last resort safety equipment available to them ejection seats.

While MacDougall survived the ejection, Casey did not. And there is no question that modern ejection seat technology the Department of National Defence planned to place in the Snowbirds fleet offers a greater chance of survival for the kinds of scenarios in which the Snowbirds fly, compared to the older ejection seats originally used in the Tutor jets.

Its led aviation safety experts across the country to ask the question: Could the jets technology have given Casey a better chance of survival?

The Department of Defence did not respond to repeated questions about the state of the ejection seats on the jets first built in 1965.

Ejection seats have a certain set of parameters called an envelope in which they will work as expected and give the person ejecting the greatest chance for survival.

State of the art ejection seats work in whats called zero-zero conditions, meaning the plane can be at zero altitude, and zero air speed, and the seat will still rocket the occupant high enough in the air for the parachute to open and the occupant to land safely.

Older ejection seats can also save lives, but they work under more limited conditions. The ejection seats original to the Snowbirds jets were manufactured by Weber Aircraft. According to several experts, the seats work from zero altitude if the plane is travelling at a speed of 60 knots. The direction of the plane also influences the effectiveness of the seat, while this is a less important factor with the zero-zero seats.

In the case of the Snowbirds, they are regularly in high-risk circumstances for ejection: They fly at high speeds, close together, at low altitude and perform aerobatics.

What matters, that most important component of any single-engine, high-speed military aircraft, is that youve got to have an ejector seat that will allow the survival of the occupant in the kind of manoeuvres that the plane performs, said John Pottinger, a longtime aviation safety expert based in Vancouver.

If the Snowbirds are still using the old Weber seats, Pottinger says, We have not reduced the risk to a level most Canadians would consider acceptable.

The military has been aware of the aging nature of the CT-114 ejection system, and has expressed a need to replace it as far back as 2015, when the national Defence Department released a report on a project then called the CT-114 Life Extension Beyond 2020.

The upgrade may include replacing wing components, replacing the ejection seat with a zero/zero capability and improving the wheel breaks to allow operations at remote locations, the 2015 document reads.

An official record of the project under the Department of National Defences investment plan, updated in January makes no mention of ejection seats. In an email, a spokesperson for the department told the Star the project is in the options analysis phase. The spokesperson did not respond to repeated questions about whether the ejection seats have been updated as part of the project.

Media reports from 2016 showed the military did test an updated ejection seat for the CT-114 Tutor off the back of a Dodge Ram. The Department of Defence did not respond to questions about whether that test led to updates to the Tutor jets.

The defence spokesperson wrote in an email that the intention of the CT-114 Life Extension Beyond 2020 is to update the CT-114 jets so theyre usable until 2030. Thats a change from previous plans detailed by the department in 2012 media reports, which said the 1960s jets would be retired by 2020.

The CT-114 Tutor aircraft has proven to be a very resilient platform to maintain and upgrade, a portion of the email reads. On-aircraft maintenance is done by RCAF technicians from 431 Sqn on a regular basis, and an additional Periodic Inspection is completed by IMP Aerospace every 400 flying hours. This includes further maintenance and repairs to ensure the aircraft remains serviceable for first-line operations.

Pottinger, who has worked in aviation safety for more than three decades, including time at Transport Canada, said that when it comes to the age of the Snowbirds fleet, the ejection seat is one of the most important safety features to keep up-to-date.

He said there are two ways to mitigate risk: You can reduce the risk of the activity itself, and you can reduce the consequences of the risky action. For example, when it comes to driving, stop signs are an example of the first way, while seatbelts are an example of the second.

Flight, especially in a single-engine, high-speed jet performing aerobatics close to the ground, is inherently risky, Pottinger said. So the choices National Defence makes about reducing the consequences of risky activity are especially important.

You decide: Can you retrofit one of the more modern ejection seats into Tutor jets, or not?

Start your morning with everything you need to know, and nothing you don't. Sign up for First Up, the Star's new daily email newsletter.

Its possible, due to the size and weight of the Tutor jets, that the answer would be no. In that case, Pottinger said the military would have to consider the cost of replacing the Tutors with newer jets, or stopping the program altogether. But to him, the risk of carrying on the Snowbirds program with inferior ejection technology is unacceptable.

Ejection was also an issue in a Snowbirds crash in October 2019, though it is unclear what went wrong.

An initial investigator report for a crash at the Atlanta Motor Speedway in Georgia, when pilot Capt. Kevin Domon-Grenier successfully ejected and survived, states that Domon-Grenier reported anomalies with the ejection system during the incident.

The crash also brought back memories of the last time a Snowbird member died in a crash.

Every May, Rob Mitchell and his former Snowbirds squadron plan to get together to remember Capt. Shawn McCaughey, who died during an air show practice exactly 13 years ago.

We call it Shawns gift to us, he said. Its that eternal connection.

Already bonded by living, travelling and flying together, Mitchell believes that the Snowbirds crew he headed in 2007 and 2008 were drawn especially close by the terrible tragedy they witnessed. On May 18, 2007, McCaugheys plane crashed during a practice show. His seatbelt failed, and the 31-year-old captain died on the spot.

A report released two years later concluded that a faulty seatbelt system the military had known about and delayed updating for five years contributed to his death.

Almost 13 years later, Mitchell watched the videos of another Snowbirds plane plunging to the ground with disbelief and dread. He saw the two streaks of smoke showing that the pilot and passenger had ejected from the CT-114 Tutor jet.

Ejection, Mitchell said, is nothing like jumping out of an airplane with a parachute. Its high-stakes safety equipment designed to shoot airplane occupants out of the aircraft high enough into the air so that the parachute expands.

The act of ejecting is a very violent thing, it propels you out of a jet at over 20 G, Mitchell said. G-force is short for gravitational force equivalent, a measure of acceleration. By comparison, jets that race in competition have a maximum G-force of 10.

The fact that the pilot of the May 17 crash survived, but Casey did not, left Mitchell with a familiar knot in his stomach, and a puzzle.

Like anything in life, theres a design limitation, air speed, altitude, nose position that is calculated when they make this machinery and there are certain envelopes for that seat and I want to know how close to that envelope they were, Mitchell said.

Being that close to it when one person makes it and one doesnt, it makes you go: What was it that made the difference?

Go here to read the rest:
Snowbirds were waiting for new ejection seats before deadly crash. Now DND wont say if gear was replaced - Toronto Star

Recommendation and review posted by Bethany Smith

The airborne retrofit & modernization (R&M) market is as vast as it is complex. With most aircraft expected to serve their operators for a span of at least 30 years, each produced airframe brings with it not only the initial cost of procurement, but a three-decades-long litany of modifications, retrofits, and Service Life Extension Programs that in some cases may surpass the initial cost of purchase. Forecast Internationals Airborne Retrofit & Modernization Forecast provides clients with an in-depth analysis of ongoing and future retrofit programs for more than 60 key aircraft operated around the globe. With the release of the Airborne Retrofit & Modernization module for Platinum Forecast System 4.4, clients can, for the first time, access the data used to generate our program reports in its entirety.

With the Platinum Forecast System, our data is sortable, customizable, and plentiful. Through years of research, our analysts have identified, analyzed, and reported on significant ongoing and speculative retrofit & modernization programs on aircraft like the Airbus A320, Lockheed Martin C-130H and more, building a library of hard data that is now available for manipulation by our clients.

A subscription to the Airborne Retrofit & Modernization module for Platinum provides not only access to our R&M-related data, but the full roster of individual platform reports and an R&M-tailored news feed, which is updated daily. Through Platinum, our clients can sort by data field, including Date Range, Platform Category, System Data Type, Category of Use and Worldwide Geography, among others, and have access to unprecedented detail, including graphics and tables/spreadsheets with computations of units/values over a 15-year forecast period. With the Airborne Retrofit & Modernization module for Platinum Forecast System 4.4, you can identify competitors in a given segment, highlight key operator nations and prime retrofit candidates within each fleet, and take advantage of opportunities as they arise.

In the weeks and months ahead, accurate and reliable market forecasts will be more critical than ever to achieving success. At this moment of global uncertainty, Forecast International is committed to ensuring you have the market intelligence you need to navigate the challenging road forward.

Read more:
Bring the Global Airborne Retrofit & Modernization Market into View - Defense & Security Monitor

Recommendation and review posted by Bethany Smith

The market research report published by QYResearch is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global COVID-19 Impact on Melatonine market. It informs readers about key trends and opportunities in the global COVID-19 Impact on Melatonine market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global COVID-19 Impact on Melatonine market.

Key companies operating in the global COVID-19 Impact on Melatonine market include , Life Extension, Pharmavite, NOW Foods, Source Naturals, BY-HEALTH, GNC, Centrum, Jamieson Vitamins, Nutraceutical Corporation, Haviland Enterprises Inc., Pharma Resources International LLC, AIE Pharmaceuticals, Gemini Pharmaceuticals, Spectrum Chemical Mfg. Corp., Nutritional Supplement Manufacturers Inc., Van Wankum Ingredients, Action Labs Inc., Softgel Nutraceuticals, Norquay Technology Inc., Arnet Pharmaceutical, Twinlab Corp., Superior Supplement Manufacturing, The Chemical Co. Melatonine

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1711659/covid-19-impact-on-global-melatonine-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global COVID-19 Impact on Melatonine market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global COVID-19 Impact on Melatonine Market Segment By Type:

, Capsule, Pills, Liquid Melatonine

Global COVID-19 Impact on Melatonine Market Segment By Application:

, Hospital, Clinic, Household, Other

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global COVID-19 Impact on Melatonine market.

Key companies operating in the global COVID-19 Impact on Melatonine market include , Life Extension, Pharmavite, NOW Foods, Source Naturals, BY-HEALTH, GNC, Centrum, Jamieson Vitamins, Nutraceutical Corporation, Haviland Enterprises Inc., Pharma Resources International LLC, AIE Pharmaceuticals, Gemini Pharmaceuticals, Spectrum Chemical Mfg. Corp., Nutritional Supplement Manufacturers Inc., Van Wankum Ingredients, Action Labs Inc., Softgel Nutraceuticals, Norquay Technology Inc., Arnet Pharmaceutical, Twinlab Corp., Superior Supplement Manufacturing, The Chemical Co. Melatonine

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1711659/covid-19-impact-on-global-melatonine-market

TOC

1 Study Coverage1.1 Melatonine Product Introduction1.2 Market Segments1.3 Key Melatonine Manufacturers Covered: Ranking by Revenue1.4 Market by Type 1.4.1 Global Melatonine Market Size Growth Rate by Type 1.4.2 Capsule 1.4.3 Pills 1.4.4 Liquid1.5 Market by Application 1.5.1 Global Melatonine Market Size Growth Rate by Application 1.5.2 Hospital 1.5.3 Clinic 1.5.4 Household 1.5.5 Other1.6 Coronavirus Disease 2019 (Covid-19): Melatonine Industry Impact 1.6.1 How the Covid-19 is Affecting the Melatonine Industry 1.6.1.1 Melatonine Business Impact Assessment Covid-19 1.6.1.2 Supply Chain Challenges 1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products 1.6.2 Market Trends and Melatonine Potential Opportunities in the COVID-19 Landscape 1.6.3 Measures / Proposal against Covid-19 1.6.3.1 Government Measures to Combat Covid-19 Impact 1.6.3.2 Proposal for Melatonine Players to Combat Covid-19 Impact1.7 Study Objectives1.8 Years Considered 2 Executive Summary2.1 Global Melatonine Market Size Estimates and Forecasts 2.1.1 Global Melatonine Revenue 2015-2026 2.1.2 Global Melatonine Sales 2015-20262.2 Melatonine Market Size by Region: 2020 Versus 2026 2.2.1 Global Melatonine Retrospective Market Scenario in Sales by Region: 2015-2020 2.2.2 Global Melatonine Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Melatonine Competitor Landscape by Players3.1 Melatonine Sales by Manufacturers 3.1.1 Melatonine Sales by Manufacturers (2015-2020) 3.1.2 Melatonine Sales Market Share by Manufacturers (2015-2020)3.2 Melatonine Revenue by Manufacturers 3.2.1 Melatonine Revenue by Manufacturers (2015-2020) 3.2.2 Melatonine Revenue Share by Manufacturers (2015-2020) 3.2.3 Global Melatonine Market Concentration Ratio (CR5 and HHI) (2015-2020) 3.2.4 Global Top 10 and Top 5 Companies by Melatonine Revenue in 2019 3.2.5 Global Melatonine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Melatonine Price by Manufacturers3.4 Melatonine Manufacturing Base Distribution, Product Types 3.4.1 Melatonine Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Melatonine Product Type 3.4.3 Date of International Manufacturers Enter into Melatonine Market3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Melatonine Market Size by Type (2015-2020) 4.1.1 Global Melatonine Sales by Type (2015-2020) 4.1.2 Global Melatonine Revenue by Type (2015-2020) 4.1.3 Melatonine Average Selling Price (ASP) by Type (2015-2026)4.2 Global Melatonine Market Size Forecast by Type (2021-2026) 4.2.1 Global Melatonine Sales Forecast by Type (2021-2026) 4.2.2 Global Melatonine Revenue Forecast by Type (2021-2026) 4.2.3 Melatonine Average Selling Price (ASP) Forecast by Type (2021-2026)4.3 Global Melatonine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026)5.1 Global Melatonine Market Size by Application (2015-2020) 5.1.1 Global Melatonine Sales by Application (2015-2020) 5.1.2 Global Melatonine Revenue by Application (2015-2020) 5.1.3 Melatonine Price by Application (2015-2020)5.2 Melatonine Market Size Forecast by Application (2021-2026) 5.2.1 Global Melatonine Sales Forecast by Application (2021-2026) 5.2.2 Global Melatonine Revenue Forecast by Application (2021-2026) 5.2.3 Global Melatonine Price Forecast by Application (2021-2026) 6 North America6.1 North America Melatonine by Country 6.1.1 North America Melatonine Sales by Country 6.1.2 North America Melatonine Revenue by Country 6.1.3 U.S. 6.1.4 Canada6.2 North America Melatonine Market Facts & Figures by Type6.3 North America Melatonine Market Facts & Figures by Application 7 Europe7.1 Europe Melatonine by Country 7.1.1 Europe Melatonine Sales by Country 7.1.2 Europe Melatonine Revenue by Country 7.1.3 Germany 7.1.4 France 7.1.5 U.K. 7.1.6 Italy 7.1.7 Russia7.2 Europe Melatonine Market Facts & Figures by Type7.3 Europe Melatonine Market Facts & Figures by Application 8 Asia Pacific8.1 Asia Pacific Melatonine by Region 8.1.1 Asia Pacific Melatonine Sales by Region 8.1.2 Asia Pacific Melatonine Revenue by Region 8.1.3 China 8.1.4 Japan 8.1.5 South Korea 8.1.6 India 8.1.7 Australia 8.1.8 Taiwan 8.1.9 Indonesia 8.1.10 Thailand 8.1.11 Malaysia 8.1.12 Philippines 8.1.13 Vietnam8.2 Asia Pacific Melatonine Market Facts & Figures by Type8.3 Asia Pacific Melatonine Market Facts & Figures by Application 9 Latin America9.1 Latin America Melatonine by Country 9.1.1 Latin America Melatonine Sales by Country 9.1.2 Latin America Melatonine Revenue by Country 9.1.3 Mexico 9.1.4 Brazil 9.1.5 Argentina9.2 Central & South America Melatonine Market Facts & Figures by Type9.3 Central & South America Melatonine Market Facts & Figures by Application 10 Middle East and Africa10.1 Middle East and Africa Melatonine by Country 10.1.1 Middle East and Africa Melatonine Sales by Country 10.1.2 Middle East and Africa Melatonine Revenue by Country 10.1.3 Turkey 10.1.4 Saudi Arabia 10.1.5 UAE10.2 Middle East and Africa Melatonine Market Facts & Figures by Type10.3 Middle East and Africa Melatonine Market Facts & Figures by Application 11 Company Profiles11.1 Life Extension 11.1.1 Life Extension Corporation Information 11.1.2 Life Extension Description, Business Overview and Total Revenue 11.1.3 Life Extension Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Life Extension Melatonine Products Offered 11.1.5 Life Extension Recent Development11.2 Pharmavite 11.2.1 Pharmavite Corporation Information 11.2.2 Pharmavite Description, Business Overview and Total Revenue 11.2.3 Pharmavite Sales, Revenue and Gross Margin (2015-2020) 11.2.4 Pharmavite Melatonine Products Offered 11.2.5 Pharmavite Recent Development11.3 NOW Foods 11.3.1 NOW Foods Corporation Information 11.3.2 NOW Foods Description, Business Overview and Total Revenue 11.3.3 NOW Foods Sales, Revenue and Gross Margin (2015-2020) 11.3.4 NOW Foods Melatonine Products Offered 11.3.5 NOW Foods Recent Development11.4 Source Naturals 11.4.1 Source Naturals Corporation Information 11.4.2 Source Naturals Description, Business Overview and Total Revenue 11.4.3 Source Naturals Sales, Revenue and Gross Margin (2015-2020) 11.4.4 Source Naturals Melatonine Products Offered 11.4.5 Source Naturals Recent Development11.5 BY-HEALTH 11.5.1 BY-HEALTH Corporation Information 11.5.2 BY-HEALTH Description, Business Overview and Total Revenue 11.5.3 BY-HEALTH Sales, Revenue and Gross Margin (2015-2020) 11.5.4 BY-HEALTH Melatonine Products Offered 11.5.5 BY-HEALTH Recent Development11.6 GNC 11.6.1 GNC Corporation Information 11.6.2 GNC Description, Business Overview and Total Revenue 11.6.3 GNC Sales, Revenue and Gross Margin (2015-2020) 11.6.4 GNC Melatonine Products Offered 11.6.5 GNC Recent Development11.7 Centrum 11.7.1 Centrum Corporation Information 11.7.2 Centrum Description, Business Overview and Total Revenue 11.7.3 Centrum Sales, Revenue and Gross Margin (2015-2020) 11.7.4 Centrum Melatonine Products Offered 11.7.5 Centrum Recent Development11.8 Jamieson Vitamins 11.8.1 Jamieson Vitamins Corporation Information 11.8.2 Jamieson Vitamins Description, Business Overview and Total Revenue 11.8.3 Jamieson Vitamins Sales, Revenue and Gross Margin (2015-2020) 11.8.4 Jamieson Vitamins Melatonine Products Offered 11.8.5 Jamieson Vitamins Recent Development11.9 Nutraceutical Corporation 11.9.1 Nutraceutical Corporation Corporation Information 11.9.2 Nutraceutical Corporation Description, Business Overview and Total Revenue 11.9.3 Nutraceutical Corporation Sales, Revenue and Gross Margin (2015-2020) 11.9.4 Nutraceutical Corporation Melatonine Products Offered 11.9.5 Nutraceutical Corporation Recent Development11.10 Haviland Enterprises Inc. 11.10.1 Haviland Enterprises Inc. Corporation Information 11.10.2 Haviland Enterprises Inc. Description, Business Overview and Total Revenue 11.10.3 Haviland Enterprises Inc. Sales, Revenue and Gross Margin (2015-2020) 11.10.4 Haviland Enterprises Inc. Melatonine Products Offered 11.10.5 Haviland Enterprises Inc. Recent Development11.1 Life Extension 11.1.1 Life Extension Corporation Information 11.1.2 Life Extension Description, Business Overview and Total Revenue 11.1.3 Life Extension Sales, Revenue and Gross Margin (2015-2020) 11.1.4 Life Extension Melatonine Products Offered 11.1.5 Life Extension Recent Development11.12 AIE Pharmaceuticals 11.12.1 AIE Pharmaceuticals Corporation Information 11.12.2 AIE Pharmaceuticals Description, Business Overview and Total Revenue 11.12.3 AIE Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020) 11.12.4 AIE Pharmaceuticals Products Offered 11.12.5 AIE Pharmaceuticals Recent Development11.13 Gemini Pharmaceuticals 11.13.1 Gemini Pharmaceuticals Corporation Information 11.13.2 Gemini Pharmaceuticals Description, Business Overview and Total Revenue 11.13.3 Gemini Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020) 11.13.4 Gemini Pharmaceuticals Products Offered 11.13.5 Gemini Pharmaceuticals Recent Development11.14 Spectrum Chemical Mfg. Corp. 11.14.1 Spectrum Chemical Mfg. Corp. Corporation Information 11.14.2 Spectrum Chemical Mfg. Corp. Description, Business Overview and Total Revenue 11.14.3 Spectrum Chemical Mfg. Corp. Sales, Revenue and Gross Margin (2015-2020) 11.14.4 Spectrum Chemical Mfg. Corp. Products Offered 11.14.5 Spectrum Chemical Mfg. Corp. Recent Development11.15 Nutritional Supplement Manufacturers Inc. 11.15.1 Nutritional Supplement Manufacturers Inc. Corporation Information 11.15.2 Nutritional Supplement Manufacturers Inc. Description, Business Overview and Total Revenue 11.15.3 Nutritional Supplement Manufacturers Inc. Sales, Revenue and Gross Margin (2015-2020) 11.15.4 Nutritional Supplement Manufacturers Inc. Products Offered 11.15.5 Nutritional Supplement Manufacturers Inc. Recent Development11.16 Van Wankum Ingredients 11.16.1 Van Wankum Ingredients Corporation Information 11.16.2 Van Wankum Ingredients Description, Business Overview and Total Revenue 11.16.3 Van Wankum Ingredients Sales, Revenue and Gross Margin (2015-2020) 11.16.4 Van Wankum Ingredients Products Offered 11.16.5 Van Wankum Ingredients Recent Development11.17 Action Labs Inc. 11.17.1 Action Labs Inc. Corporation Information 11.17.2 Action Labs Inc. Description, Business Overview and Total Revenue 11.17.3 Action Labs Inc. Sales, Revenue and Gross Margin (2015-2020) 11.17.4 Action Labs Inc. Products Offered 11.17.5 Action Labs Inc. Recent Development11.18 Softgel Nutraceuticals 11.18.1 Softgel Nutraceuticals Corporation Information 11.18.2 Softgel Nutraceuticals Description, Business Overview and Total Revenue 11.18.3 Softgel Nutraceuticals Sales, Revenue and Gross Margin (2015-2020) 11.18.4 Softgel Nutraceuticals Products Offered 11.18.5 Softgel Nutraceuticals Recent Development11.19 Norquay Technology Inc. 11.19.1 Norquay Technology Inc. Corporation Information 11.19.2 Norquay Technology Inc. Description, Business Overview and Total Revenue 11.19.3 Norquay Technology Inc. Sales, Revenue and Gross Margin (2015-2020) 11.19.4 Norquay Technology Inc. Products Offered 11.19.5 Norquay Technology Inc. Recent Development11.20 Arnet Pharmaceutical 11.20.1 Arnet Pharmaceutical Corporation Information 11.20.2 Arnet Pharmaceutical Description, Business Overview and Total Revenue 11.20.3 Arnet Pharmaceutical Sales, Revenue and Gross Margin (2015-2020) 11.20.4 Arnet Pharmaceutical Products Offered 11.20.5 Arnet Pharmaceutical Recent Development11.21 Twinlab Corp. 11.21.1 Twinlab Corp. Corporation Information 11.21.2 Twinlab Corp. Description, Business Overview and Total Revenue 11.21.3 Twinlab Corp. Sales, Revenue and Gross Margin (2015-2020) 11.21.4 Twinlab Corp. Products Offered 11.21.5 Twinlab Corp. Recent Development11.22 Superior Supplement Manufacturing 11.22.1 Superior Supplement Manufacturing Corporation Information 11.22.2 Superior Supplement Manufacturing Description, Business Overview and Total Revenue 11.22.3 Superior Supplement Manufacturing Sales, Revenue and Gross Margin (2015-2020) 11.22.4 Superior Supplement Manufacturing Products Offered 11.22.5 Superior Supplement Manufacturing Recent Development11.23 The Chemical Co. 11.23.1 The Chemical Co. Corporation Information 11.23.2 The Chemical Co. Description, Business Overview and Total Revenue 11.23.3 The Chemical Co. Sales, Revenue and Gross Margin (2015-2020) 11.23.4 The Chemical Co. Products Offered 11.23.5 The Chemical Co. Recent Development 12 Future Forecast by Regions (Countries) (2021-2026)12.1 Melatonine Market Estimates and Projections by Region 12.1.1 Global Melatonine Sales Forecast by Regions 2021-2026 12.1.2 Global Melatonine Revenue Forecast by Regions 2021-202612.2 North America Melatonine Market Size Forecast (2021-2026) 12.2.1 North America: Melatonine Sales Forecast (2021-2026) 12.2.2 North America: Melatonine Revenue Forecast (2021-2026) 12.2.3 North America: Melatonine Market Size Forecast by Country (2021-2026)12.3 Europe Melatonine Market Size Forecast (2021-2026) 12.3.1 Europe: Melatonine Sales Forecast (2021-2026) 12.3.2 Europe: Melatonine Revenue Forecast (2021-2026) 12.3.3 Europe: Melatonine Market Size Forecast by Country (2021-2026)12.4 Asia Pacific Melatonine Market Size Forecast (2021-2026) 12.4.1 Asia Pacific: Melatonine Sales Forecast (2021-2026) 12.4.2 Asia Pacific: Melatonine Revenue Forecast (2021-2026) 12.4.3 Asia Pacific: Melatonine Market Size Forecast by Region (2021-2026)12.5 Latin America Melatonine Market Size Forecast (2021-2026) 12.5.1 Latin America: Melatonine Sales Forecast (2021-2026) 12.5.2 Latin America: Melatonine Revenue Forecast (2021-2026) 12.5.3 Latin America: Melatonine Market Size Forecast by Country (2021-2026)12.6 Middle East and Africa Melatonine Market Size Forecast (2021-2026) 12.6.1 Middle East and Africa: Melatonine Sales Forecast (2021-2026) 12.6.2 Middle East and Africa: Melatonine Revenue Forecast (2021-2026) 12.6.3 Middle East and Africa: Melatonine Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis13.1 Market Opportunities and Drivers13.2 Market Challenges13.3 Market Risks/Restraints13.4 Porters Five Forces Analysis13.5 Primary Interviews with Key Melatonine Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis14.1 Value Chain Analysis14.2 Melatonine Customers14.3 Sales Channels Analysis 14.3.1 Sales Channels 14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix16.1 Research Methodology 16.1.1 Methodology/Research Approach 16.1.2 Data Source16.2 Author Details16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See more here:
COVID-19 Impact on Melatonine Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026 - News Distinct

Recommendation and review posted by Bethany Smith

The S-adenosylmethionine (SAM-e) Market an off-the-shelf research report for the year 2020-2026 has been recently added by Market Insights Reports to get an in-depth analysis of different attributes of industries and providing timely access to accurate, reliable and unbiased analysis of the market. The data provided related to the Market Size in value and volume*, top market segments driving sales and revenue, top companies, the share of the market in the market and the top countries which account for the maximum production and consumption.

The major manufacturers covered in this report:

Doctors Best, NutraLife, Jarrow Formulas, Now Foods, Life Extension, Source Naturals, California Gold Nutrition, Metabolic Maintenanc, and Others.

We aimed to provide most segmented consumption and sales data of different types of S-adenosylmethionine (SAM-e), downstream consumption fields and competitive landscape in different regions and countries around the world, this report analyzes the latest market data from the primary and secondary authoritative source.

Types Of Global S-adenosylmethionine (SAM-e) Market is Segmented as Follows:

Chemical Synthesis

Fermentation

Enzymatic Conversion

and others.

Sample PDF Copy of S-adenosylmethionine (SAM-e) Market 2019 :

https://www.marketinsightsreports.com/reports/06022058996/covid-19-impact-on-global-s-adenosylmethionine-sam-e-market-insights-forecast-to-2026/inquiry?mode=MH82

Application Of Global S-adenosylmethionine (SAM-e) Market is Segmented as Follows:

Scientific Research

Clinical Treatment

Others

and others.

We aim to deliver a high quality report with a relatively low cost thus delivering a optimum ROI and helping those involved in making informed, analytically driven decisions. Each of our reports has a database that has been researched and honed for the past 5 to 7 years, Along with this secondary sources referred to and studied include press releases, financial statements, analyst reports and other paid sources.

Special Offer: Avail Up to 20% Discount On S-adenosylmethionine (SAM-e) Report:

https://www.marketinsightsreports.com/reports/06022058996/covid-19-impact-on-global-s-adenosylmethionine-sam-e-market-insights-forecast-to-2026/discount?mode=MH82

Geographical Regional Analysis :

The research mainly covers S-adenosylmethionine (SAM-e) market in

-North America (United States, Canada and Mexico)

-Europe industry (Germany, France, UK, Russia and Italy)

-Asia-Pacific (Southeast Asia, China, Korea, India and Japan)

-South America industry (Brazil, Argentina, Colombia)

-Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Important Features that are under Offering and Key Highlights of the Reports:

-Detailed overview of S-adenosylmethionine (SAM-e) Market

-Changing market dynamics of the industry

-In-depth market segmentation by Type, Application etc.

-Historical, current and projected market size in terms of volume and value

-Recent industry trends and developments

-Competitive landscape of S-adenosylmethionine (SAM-e) Plant Market

-Strategies of key players and product offerings

-Potential and niche segments/regions exhibiting promising growth

This data is provided from 2014 to 2019 in actual and has been forecasted from 2020 to 2025 keeping in mind the current market trends, micro and macroeconomic factors and other legal and environmental factors affecting the market.

Buy complete S-adenosylmethionine (SAM-e) Market report at :

https://www.marketinsightsreports.com/reports/06022058996/covid-19-impact-on-global-s-adenosylmethionine-sam-e-market-insights-forecast-to-2026?mode=MH82

We also offer customization on reports based on specific client requirement:

1- Country level analysis for any 5 countries of your choice.

2- Competitive analysis of any 5 key market players.

3- 40 analyst hours to cover any other data points

Contact Us:

Irfan Tamboli (Head of Sales) Market Insights ReportPhone: + 1704 266 3234 | +91-750-707-8687sales@marketinsightsreports.com | irfan@marketinsightsreports.com

See original here:
S-adenosylmethionine (SAM-e) Market Production, Revenue And Status forecast 2020 to 2026 - News Collective

Recommendation and review posted by Bethany Smith

COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026, Key Regions, Types and Application, By Players, Type, Application, Marketing Channel and Region

This report focuses on the COVID-19 Impact on Global Male Breast Cancer Treatment Market status, future forecast, growth opportunity, key market and key players. The study objectives are to present COVID-19 Impact on Global Male Breast Cancer Treatment Market development in United States, Europe and China.

In 2019, COVID-19 Impact on Global Male Breast Cancer Treatment Market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2020-2025.

The report also summarizes the various types of COVID-19 Impact on Global Male Breast Cancer Treatment Market. Factors that influence the market growth of particular product category type and market status for it. A detailed study of COVID-19 Impact on Global Male Breast Cancer Treatment Market has been done to understand the various applications of the products usage and features. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

Get sample copy of this[emailprotected] https://www.lexisbusinessinsights.com/request-sample-133783

Top Key Players: Pfizer, Roche, GlaxoSmithKline, Sanofi, Novartis, Bayer, Bristol-Myers Squibb, Eli Lilly, AstraZeneca, Teva Pharmaceutical, Sun Pharmaceutical, BioNumerik Pharmaceuticals, Seattle Genetics, and Accord Healthcare

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they COVID-19 Impact on Global Male Breast Cancer Treatment Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the key market trends impacting the growth of COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the challenges to market growth?

Who are the key vendors in COVID-19 Impact on Global Male Breast Cancer Treatment Market?

What are the market opportunities and threats faced by the vendors in COVID-19 Impact on Global Male Breast Cancer Treatment Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia COVID-19 Impact on Global Male Breast Cancer Treatment Market;

3.) The North American COVID-19 Impact on Global Male Breast Cancer Treatment Market;

4.) The European COVID-19 Impact on Global Male Breast Cancer Treatment Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

COVID-19 Impact on Global Male Breast Cancer Treatment Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2026

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-133783

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Director- Business Development)

US: +1 210 907 4145

APAC: +91 9867799788

[emailprotected]

http://www.lexisbusinessinsights.com

See the original post here:
COVID-19 Impact on Global Male Breast Cancer Treatment Market Size, Status and Forecast 2020-2026,Top Key Players: Pfizer, Roche, GlaxoSmithKline,...

Recommendation and review posted by Bethany Smith

People usually volunteer to donate stem cells for an allogeneic transplant either because they have a loved one or friend who needs a match or because they want to help people. Some people give their stem cells so they can get them back later if they need an autologous transplant.

People who want to donate stem cells or join a volunteer registry can speak with a health care provider or contact the National Marrow Donor Program to find the nearest donor center. Potential donors are asked questions to make sure they are healthy enough to donate and dont pose a risk of infection to the recipient. For more information about donor eligibility guidelines, contact Be the Match or the donor center in your area.

Be the Match (formerly the National Marrow Donor Program)Toll-free number: 1-800-MARROW-2 (1-800-627-7692)Website: http://www.bethematch.org

A simple blood test is done to learn the potential donors HLA type. There may be a one-time, tax-deductible fee of about $75 to $100 for this test. People who join a volunteer donor registry will most likely have their tissue type kept on file until they reach age 60.

Pregnant women who want to donate their babys cord blood should make arrangements for it early in the pregnancy, at least before the third trimester. Donation is safe, free, and does not affect the birth process.

If a possible stem cell donor is found to be a good match for a recipient, steps are taken to teach the donor about the transplant process and make sure he or she is making an informed decision. If a person decides to donate, a consent form must be signed after the risks of donating are fully discussed. The donor is not pressured to take part. Its always a choice.

If a person decides to donate, a medical exam and blood tests will be done to make sure the donor is in good health.

Stem cells may be collected from these 3 different sources:

Each method of collection is explained here.

This process is often called bone marrow harvest. Its done in an operating room, while the donor is under general anesthesia (given medicine to put them into a deep sleep so they dont feel pain). The marrow cells are taken from the back of the pelvic (hip) bone. The donor lies face down, and a large needle is put through the skin and into the back of the hip bone. Its pushed through the bone to the center and the thick, liquid marrow is pulled out through the needle. This is repeated several times until enough marrow has been taken out (harvested). The amount taken depends on the donors weight. Often, about 10% of the donors marrow, or about 2 pints, are collected. This takes about 1 to 2 hours. The body will replace these cells within 4 to 6 weeks. If blood was taken from the donor before the marrow donation, its often given back to the donor at this time.

After the bone marrow is harvested, the donor is taken to the recovery room while the anesthesia wears off. The donor may then be taken to a hospital room and watched until fully alert and able to eat and drink. In most cases, the donor is able to leave the hospital within a few hours or by the next morning.

The donor may have soreness, bruising, and aching at the back of the hips and lower back for a few days. Over-the-counter pain medications or nonsteroidal anti-inflammatory drugs are helpful. Some people may feel tired or weak, and have trouble walking for a few days. The donor might be told to take iron supplements until the number of red blood cells returns to normal. Most donors get back to their usual activities in 2 to 3 days. But it could take 2 or 3 weeks before they feel completely back to normal.

There arent many risks for donors and serious complications are rare. But bone marrow donation is a surgical procedure. Rare complications could include anesthesia reactions, infection, nerve or muscle damage, transfusion reactions (if a blood transfusion of someone elses blood is needed this doesnt happen if you get your own blood), or injury at the needle insertion sites. Problems such as sore throat or nausea may be caused by anesthesia.

Allogeneic stem cell donors do not have to pay for the harvesting because the recipients insurance company usually covers the cost. Even so, be sure to ask about insurance coverage before you decide to have the bone marrow harvest done.

Once the cells are collected, they are filtered through fine mesh screens. This prevents bone or fat particles from being given to the recipient. For an allogeneic or syngeneic transplant, the cells may be given to the recipient through a vein soon after they are harvested. Sometimes theyre frozen, for example, if the donor lives far away from the recipient.

For several days before starting the donation process, the donor is given a daily injection (shot) of a drug that causes the bone marrow to make and release a lot of stem cells into the blood. Filgrastim can cause some side effects, the most common being bone pain and headaches. These may be helped by over-the-counter pain medications or nonsteroidal anti-inflammatory drugs. Nausea, sleeping problems, low-grade (mild) fevers, and tiredness are other possible effects. These go away once the injections are finished and collection is completed.

After the shots, blood is removed through a catheter (a thin, flexible plastic tube) thats put in a large vein in the arm. Its then cycled through a machine that separates the stem cells from the other blood cells. The stem cells are kept while the rest of the blood is returned to the donor, often through the same catheter. (In some cases, a catheter may be put in each arm one takes out blood and the other puts it back.) This process is called apheresis. It takes about 2 to 4 hours and is done as an outpatient procedure. Often the process needs to be repeated daily for a few days, until enough stem cells have been collected.

Possible side effects of the catheter can include trouble placing the catheter in the vein, blockage of the catheter, or infection of the catheter or at the area where it enters the vein. Blood clots are another possible side effect. During the apheresis procedure, donors may have problems caused by low calcium levels from the anti-coagulant drug used to keep the blood from clotting in the machine. These can include feeling lightheaded or tingly, and having chills or muscle cramps. These go away after donation is complete, but may be treated by giving the donor calcium supplements.

The process of donating cells for yourself (autologous stem cell donation) is pretty much the same as when someone donates them for someone else (allogeneic donation). Its just that in autologous stem cell donation the donor is also the recipient, giving stem cells for his or her own use later on. For some people, there are a few differences. For instance, sometimes chemotherapy (chemo) is given before the growth factor drug is used to tell the body to make stem cells. Also, sometimes it can be hard to get enough stem cells from a person with cancer. Even after several days of apheresis, there may not be enough for the transplant. This is more likely to be a problem if the patient has had certain kinds of chemo in the past, or if they have an illness that affects their bone marrow.

Cord blood is the blood thats left in the placenta and umbilical cord after a baby is born. Collecting it does not pose any health risk to the infant or the mother. Cord blood transplants use blood that would otherwise be thrown away. After the umbilical cord is clamped and cut, the placenta and umbilical cord are cleaned. The cord blood is put into a sterile container, mixed with a preservative, and frozen until needed.

Some parents choose to donate their infants cord blood to a public blood bank, so that it may be used by anyone who needs it. Many hospitals collect cord blood for donation, which makes it easier for parents to donate. Parents can donate their newborns cord blood to volunteer or public cord blood banks at no cost. For more about donating your newborns cord blood, call 1-800-MARROW2 (1-800-627-7692) or visit Be the Match.

Other parents store their newborns cord blood in private cord blood banks just in case the child or a close relative needs it someday. If you want to donate or bank (save) your childs cord blood, youll need to arrange it before the baby is born. Some banks require you to set it up before the 28th week of pregnancy, although others accept later setups. Among other things, youll be asked to answer health questions and sign a consent form.

Parents may want to bank their childs cord blood if the family has a history of diseases that may benefit from stem cell transplant. There are several private companies offer this service. But here are some things to think about:

More information on private family cord blood banking can be found at the Parents Guide to Cord Blood Foundation. You can visit their website at http://www.parentsguidecordblood.org.

Continued here:
Donating Stem Cells and Bone Marrow

Recommendation and review posted by Bethany Smith

Bone marrowaspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.

Get Access to sample pages @https://www.trendsmarketresearch.com/report/sample/3184

The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.Europe and North America spearheaded the market as of 2016, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.

In 2016, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy.

Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.

Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others

Covid 19 ImpactAnalysis@https://www.trendsmarketresearch.com/report/covid-19-analysis/3184

Read this article:
Bone Marrow Processing System Market Incisive Insights Regarding Major Regions, Key Players And Opportunities Up To 2025 - Kentucky Journal 24

Recommendation and review posted by Bethany Smith

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Know the Growth Opportunities in Emerging Markets

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

The regional analysis covers:

Order this Report TOC for Detailed Statistics

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1787<ype=S

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Continued here:
Stem Cell Therapy Market Analysis and Demand 2017 2025 - Cole of Duty

Recommendation and review posted by Bethany Smith

Mesenchymal Stem Cells Market Trends by Manufacturers, States, Type and Application, Forecast to 2019 2027

Global Mesenchymal Stem Cells Market: Snapshot

The increasing use of mesenchymal stem cells (MSCs) for the treatment of diseases and disabilities of the growing aging population is having a positive influence on the global mesenchymal stem cells market. Mesenchymal stem cells are adult stem cells that are of various types such as adipocytes, osteocytes, monocytes, and chondrocytes.

The main function of mesenchymal stem cells is to replace or repair damaged tissue.

Report Overview @www.transparencymarketresearch.com/mesencharket.html

Mesenchymal stem cells are multipotent, i.e. they can produce more than one type of specialized cells.

These specialized cells have their own distinguishing shapes, structures, and functions, with each of them belonging to a particular tissue.

Mesenchymal stem cells are traditionally found in the bone marrow. However, these cells can also be separated from other tissues such as cord blood, fallopian tube, peripheral blood, and fetal liver and lung.

Mesenchymal stem cells have long thin cell bodies containing a large nucleus. MSCs have enormous capacity for renewal keeping multipotency.

Due to these virtues, mesenchymal stem cells have huge therapeutic capacity for tissue repair.

Get Brochure of the Report @www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells can differentiate into a number of cell types that belong to our skeletal tissues that include cartilage, bone, and fat. Research is underway to discover if mesenchymal stem cells can be used to treat bone and cartilage diseases.

Scientists are also exploring the possibility if mesenchymal stem cells differentiate into other type of cells apart from skeletal tissues. This includes nerve cells, liver cells, heart muscle cells, and endothelial cells.

This will lead to mesenchymal stem cells to be used to treat other diseases.

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue.

Request For Covid19 Impact Analysis http://www.transparencymarketresearch.com/sample/p_id=26735

Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation.

These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area.

The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses.

Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases.

Pre Book Now @www.transparencymarketresearch.com/checkoump;ltype=S

Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex.

In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues.

Traditionally the MSCs were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSCs from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing.

In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Read our Case study at :www.transparencymarketresearch.com/casestug-start-up

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives.

Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

See original here:
Mesenchymal Stem Cells Market trends by manufacturers, states, type and application, forecast to 2019 2027 - WhaTech Technology and Markets News

Recommendation and review posted by Bethany Smith

The Phase 2 study will assess the safety and efficacy of Longeveron's stem cell treatment under Japan's accelerated regulatory pathway for regenerative medicine.

MIAMI, June 1, 2020 /PRNewswire/ --Longeveron LLC announced today that Japan's Pharmaceutical and Medical Devices Agency (PMDA) (the Japanese agency akin to the United States' Food & Drug Administration) approved a Clinical Trial Notification (CTN) application (akin to an Investigational New Drug Application or "IND" in the US regulatory system), approving the initiation of a Phase 2 clinical trial evaluating the safety and efficacy of Longeveron's Mesenchymal Stem Cells (LMSCs) for the treatment of Aging Frailty in Japanese patients. This is another key milestone for Longeveron's Aging Frailty program, which includes two ongoing Phase 2 clinical trials in the U.S.

"We are extremely pleased to achieve this significant milestone," said Geoff Green, President of Longeveron."This study is designed to determine whether the transplant of donor-derived mesenchymal stem cells can improve healthspan in mild to moderately frail patients, thereby improving functionality and potentially lowering their risk of disability, and dependence on others for care."

Aging Frailty is a common, but reversible, life-threatening geriatric condition affecting millions of Japanese over the age of 65.Frail individuals are vulnerable to adverse health outcomes compared to their age-matched peers despite sharing similar comorbidities and demographics.Clinically, frailty manifests as a combination of symptoms that may include loss of muscle and decreased strength, slowed walking (sarcopenia), lower activity and energy levels, poor endurance, nutritional deficiencies, weight loss and fatigue.Collectively, these lead to overall decline in functionality, and increased risk of disability, dependency, and death.

"The biology of frailty is complex, and includes diminished stem cell activity, reduced ability to repair and regenerate tissue, and immunosenescence (deterioration of the immune system) and chronic systemic inflammation," said Dr. Anthony Oliva, Senior Scientist at Longeveron. "LMSCs have multiple mechanisms of action that can potentially address all of these issues, and thus make them extremely attractive as a therapeutic candidate for the unmet medical need of Aging Frailty."

The planned study is an investigator-initiated, randomized, double-blind, placebo-controlled design,and will be conducted at Juntendo University Hospital (Tokyo) and Japan's National Center for Geriatrics and Gerontology (NCGG) in Nagoya.The study's Principal Investigator, Dr. Hidenori Arai, President of the NCGG, commented that "Japan has one of the oldest and fastest aging societies in the world, with nearly 30% of Japan's citizens over the age of 65.Preventing and reversing functional decline associated with frailty is one of the nation's top priorities, and Longeveron's regenerative medicine approach is an exciting and innovative potential therapeutic option.With the disproportionate infection and mortality rate of older people with COVID-19 and Influenza infection, it is critically important to rapidly test treatments that may be effective."

In Japan, the "Pharmaceutical and Medical Device Act" and the "Act on the Safety of Regenerative Medicine" came into effect in 2014. Under this system, a "Time-limited Conditional Approval" option exists, which allows a manufacturer to conditionally sell regenerative medicine products while proceeding with its Phase 3 clinical trial.

Longeveron's Aging Frailty Research Program

Longeveron sponsors the most extensive and advanced Aging Frailty clinical research program in the world, with more than 200 patients treated with LMSCs worldwide.In the U.S., two clinical trials are currently ongoing:

About LMSCs

Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) is a regenerative medicine product sourced from the bone marrow of young healthy adult donors.LMSCs are culture expanded under the FDA's current good manufacturing practices (cGMP) to high standards, and maintained as individual "off-the-shelf" doses.

About Longeveron LLC

Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron's mission is to provide biological solutions for aging-related diseases and life-threatening conditions, and is dedicated to developing safe and effective cell-based therapeutics for unmet medical needs such as Aging Frailty, the Metabolic Syndrome, Alzheimer's Disease, Acute Respiratory Distress Syndrome (ARDS) from COVID-19 infection, and congenital heart defects in children (hypoplastic left heart syndrome).

For information please contact:

Paul Lehr, JDplehr@longeveron.com305-338-6257

Related Images

longeveron.png LONGEVERON Longeveron - Biological Solutions for Aging

Related Links

Website

View original content to download multimedia:http://www.prnewswire.com/news-releases/longeveron-announces-japanese-approval-of-clinical-trial-for-treatment-of-aging-frailty-with-longeverons-stem-cells-301068215.html

SOURCE LONGEVERON

Read more from the original source:
Longeveron Announces Japanese Approval of Clinical Trial for Treatment of Aging Frailty With Longeveron's Stem Cells - Yahoo Finance

Recommendation and review posted by Bethany Smith